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The porphyrias comprise of several rare metabolic disorders in which a crucial 
enzymatic step in the biosynthesis of haem is affected, mostly due to a genetic defect. 
The current project focused on two major disease groups of the porphyrias; acute 
hepatic porphyria (AHP) and porphyria cutanea tarda (PCT).  
AHP presents clinically as neurovisceral acute attacks, usually in adulthood, usually 
requiring inpatient care. Only a small proportion of AHP gene mutation carriers 
develop symptoms and repeat attacks are common in a minimal, mostly female 
subtype. It has been proposed that the precursors of haem, which are 
characteristically overproduced in symptomatic AHP, and to a lesser extent 
genetically predisposed gene carriers, may be carcinogenic. Indeed AHP is 
associated with an increased risk of hepatocellular carcinoma (HCC), although the 
magnitude of this risk remains unclear and it is uncertain if AHP increases risk of 
other malignancies. The acute attacks and/or chronic symptoms of AHP may also 
affect daily living and put patients at risk of sick leave absences and disability 
pension. In addition to HCC, AHP is associated with other long-term complications, 
such as kidney failure and hypertension, which may lead to premature death.  
PCT presents clinically in the form of photosensitivity, blistering, crusts and fragile 
skin, as a result of abnormal quantities of porphyrins in the skin. Liver damage and 
iron overload are common in PCT. PCT is also strongly associated with the hepatitis 
C virus (HCV) infection, abuse of alcohol, hemochromatosis and the use of 
oestrogens. Consequently, PCT may be associated with premature mortality. PCT 
may also be a risk factor for HCC and other cancers, but the evidence is unclear.  
Aims: 
The current project aimed to investigate the long-term consequences of AHP and 
PCT. Specifically, we aimed to investigate the risk of malignancies, with a particular 
interest in the risk of HCC. We also aimed to investigate the risk of premature death, 
both overall and disease-specific mortality. Finally, we investigated morbidity in 
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persons with AHP and if there was an increased risk of long-term sick leave and/or 
disability pension compared to the general population.       
Methods:  
We conducted three nationwide, registry-based cohort studies. Several compulsory 
data sources were record linked to the Norwegian Porphyria Registry, originally in 
2012 and again in 2018. All Norwegian adult residents comprising of over 5 million 
persons comprised the reference populations. Study I investigated cancer risk in AHP 
from 2000 to 2011. Study II investigated cancer and mortality risk in persons with 
PCT from 2000 to 2016 and study III investigated long-term sick leave, disability 
leave and mortality in persons with AHP from 1992 to 2017, 1992 to 2016 and 1996 
to 2017, respectively. The absolute risk was assessed by calculating annual 
incidence, and we conducted survival analysis using several regression techniques to 
compare risk between persons with AHP/PCT and the reference population, 
adjusting for age, sex and educational attainment. We also calculated risk stratified 
by subtypes of AHP and PCT, namely between persons with symptomatic disease, at 
some point in time, and asymptomatic AHP gene carriers and between persons with 
sporadic and familial PCT. Sex differences in study I was investigated by a meta-
analysis of several published cohort studies. Lastly, given that HCC and PCT share 
similar risk factors, which would confound our results, we also compared persons 
with PCT to persons with a history of alcohol abuse in study II.   
Results: 
We found evidence of a 108-fold (95% confidence interval (CI): 56, 207) and a 20-
fold (95% CI: 8.8, 44.0) increased risk of HCC in persons with AHP and PCT, 
respectively. The risk was higher for women than men with AHP according to the 
findings of the meta-analysis in study I. The risk remained, although to a much 
smaller extent when comparing the risk of HCC in persons with PCT to persons with 
a history of alcohol abuse/dependence in study II. We also found evidence that AHP 
may be associated with a small increased risk of kidney and endometrial cancers and 
PCT associated with an increased risk of gallbladder and biliary tract cancer. A 1.5-
fold increased overall risk of premature death was observed in individuals with PCT 
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in study II, whereas a sensitivity analysis suggested that there was no increased risk 
of premature death in persons with AHP in study III, despite an increased risk of 
mortality due to HCC. Lastly, in study III, persons with AHP had a 1.5-fold increased 
risk of long-term sick leave (95% CI 1.3, 1.7) and a 1.9-fold increased risk of 
disability pension (95% CI 1.5, 2.4). The risk was even greater in persons with 
symptomatic AHP, but not elevated for asymptomatic AHP gene carriers. 
Conclusions:  
Persons with PCT and AHP are at substantially increased risk of HCC compared to 
the general population. Although lifestyle factors likely contribute to these 
observations in persons with PCT, something specific about PCT itself may 
contribute to the pathophysiology of HCC. For persons with AHP, who do not 
generally differ from the general population concerning HCC risk factors, our study 
supports previous findings that PLC is a serious life-threatening long-term 
consequence of AHP, and supports the idea that persons 50 years or older from this 
group would benefit from selective surveillance. Morbidity due to AHP also appears 
to result in more long-term sick leave absences from work and disability pension in 
persons with symptomatic AHP. Early diagnosis, counselling about precipitating 
factors and routine follow-up of symptomatic AHP gene carriers is, therefore, 
recommended. 
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1. Background 
The porphyrias consist of several rare mainly hereditary metabolic disorders. The 
laboratory diagnosis and specialised treatment of the porphyrias have received a 
great deal of attention over the past three decades. This has led to marked 
improvements in health, especially concerning acute attacks of acute hepatic 
porphyria (AHP). However, research has recently begun to focus on the natural 
history and long-term consequences of the porphyrias, both concerning morbidity 
and mortality, which have been traditionally less in focus.   
The background of this thesis will introduce the porphyrias, including the underlying 
biochemical mechanisms and clinical presentations, and discuss known long-term 
consequences, particularly hepatocellular carcinoma (HCC) and access to long-term 
sick leave and the disability pension as well as life expectancy.  
1.1 Porphyrias: disorder overview and classification  
The porphyrias comprise of several rare, mostly hereditary metabolic diseases. Each 
type is caused by a specific deficiency of an enzyme involved in the eight steps of 
haem bio-synthesis (Figure 1) (1). This altered activity of an enzyme can lead to the 
accumulation of the haem precursors 5-aminolaevulinic acid (ALA), 
porphobilinogen (PBG), and/or porphyrins in individuals with porphyria, which can 
have diverse acute and chronic clinical effects (2). Porphyrins are an essential 
building block of haem, which is vital for oxygen transportation and metabolism in 
all human cells (3). Haem is in particular abundance in the erythropoietic cells, 
mostly for the production of haemoglobin (4), and the liver parenchymal cells, for 
the metabolism of exogenous compounds, such as drugs and chemicals (5). 
Symptoms of the disorders can present as acute attacks of abdominal pain and 
neurovisceral symptoms (acute intermittent porphyria (AIP)), cutaneous symptoms 
(porphyria cutanea tarda (PCT), congenital erythropoietic porphyria (CEP), 
erythropoietic protoporphyria (EPP) and X-linked erythropoietic protoporphyria 
(XLEPP)) or both (hereditary coproporphyria (HCP) and variegate porphyria (VP)). 
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Diagnosis in symptomatic patients is based on the demonstration of increased haem 
precursors in urine, blood and/or faeces. Porphyria occurs in both sexes and all ethnic 
groups. AHP refers to four acute forms of porphyria where the enzyme deficiency 
becomes rate-limiting in the liver: AIP, VP, HCP, and ALAD deficiency. However, 
given the extreme rarity of ALAD deficiency, the term AHP usually refers to AIP, 
VP, and HCP, which will be the case hereafter. The current project focussed on the 
long-term consequences of AHP and PCT only. 
Figure 1. The haem biosynthesis pathway. Reprinted from “Porphyrias,” by Puy, H., 
Gouya, L. & Debach, J.C. 2010, Lancet, Vol. 375 (9718), 924-937.  
 
Green boxes=hepatic porphyrias. Red boxes=erythropoietic porphyrias. ALA=5-aminolaevulinic acid. 
PBG=porphobilinogen. I, III, or IX=type isomers. ALAS=ALA synthase. ALAD=ALA-dehydratase. 
PBGD=porphobilinogen deaminase. UROIIIS=uroporphyrinogen III synthase. UROD=uroporphyrinogen 
decarboxylase. CPO=coproporphyrinogen oxidase. PPOX=protoporphyrinogen oxidase. 
FECH=ferrochelatase. Fe2+=ferrous iron. 
 
1.1.1 Acute hepatic porphyria (AHP) 
Epidemiology and pathogenesis 
AHP is inherited in an autosomal dominant fashion, meaning that it is 50 per cent 
likely that an affected parent will pass on the variant to their child and there is 
roughly a similar sex ratio of affected gene carriers. Although traditionally AHP was 
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thought to be a monogenic disorder, caused by a single gene, new evidence suggests 
that AIP at least follows an oligogenic inheritance pattern, and additional genetic and 
environmental triggers are required for their expression (6). For the current thesis, 
‘asymptomatic’ AHP gene carriers refers to individuals who never have had 
symptoms of AHP but carry an AHP gene mutation, while ‘symptomatic’ AHP are 
individuals who have experienced at least one episode due to an acute attack of 
AHP.  Clinical penetrance is very low, and although it was previously estimated that 
10 per cent of mutation carriers develop symptoms (1), a more recent genetic study 
estimates clinical penetrance to be as low as one per cent for AIP (7). AIP is the most 
common form of AHP. The incidence of individuals with symptomatic AHP across 
Europe over three years was estimated at 0.13 per one million for AIP and 0.07 per 
million for VP (8). The incidence was relatively similar across countries except for 
Sweden, in which the incidence rate was four times greater due to a founder effect in 
the Northern regions by the mutation W198X (9). Likely, Norway may also have a 
slightly higher incidence due to this founder effect (10), although this was not 
demonstrated by Elder et al, which may be because of the small study period of only 
three years. HCP is rarer still. Although a founder effect also accounts for a higher 
incidence of VP in South Africa (11). At the time of writing the current thesis, over 
400 disease-associated sequence variants have been recognised in AIP. However, 
disease severity is highly variable between individuals, and there is no convincing 
evidence that a particular mutation is associated with disease severity (12).  
Known endogenous and exogenous triggers that may induce clinical penetrance 
include barbiturates and other porphyrinogenic drugs, alcohol (13), fasting (14), 
psychological and physical stress (15), infection and menstruation (1, 16), with drug 
exposure a frequent trigger of an acute attack in VP and hormonal factors more 
important in AIP (17). These factors induce hepatic delta-aminolevulinic acid 
synthase 1 (ALAS1), the rate-limiting enzyme in the production of haem in the liver, 
either directly or indirectly by increasing the demand for haem in the liver (1). 
Several theories have been proposed regarding the pathophysiology of neuropathic 
symptoms in AHP, although the exact mechanism remains unknown. Currently, the 
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hypothesis with the most persuasive evidence is that circulating levels of ALA and/or 
PBG, which are produced in the liver, are responsible for the neuropathic symptoms 
of AHP (18). ALA is structurally similar to the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) and can interact with GABA receptors (19). However, 
the correlation between ALA and PBG and acute attacks is variable, and 
asymptomatic AHP gene carriers may have high urinary excretion of ALA and PBG 
without ever having had symptoms of an acute attack (20). Clinical expression of 
AHP is uncommon before puberty and after menopause and more common in 
females between the ages of 30 to 40 years of age (1, 21-23). Most patients have one 
to a few attacks over their lifetime, whereas, a small sub-set (10%) of mostly women 
develop recurrent attacks of four or more a year (1, 21).  
Clinical presentation 
The neurovisceral attacks caused by AHP are mostly characterised by severe 
abdominal pain that lasts longer than 24 hours, but rarely longer than two weeks (15). 
Pain in the extremities and muscle weakness is also common. Peripheral neuropathy, 
motor weakness, electrolyte disturbances, hypertension, tachycardia, and seizures can 
occur (17, 24-26). Neuropathy can sometimes lead to paralysis of the respiratory 
muscles and very rarely death (1). Although the three disorders of AHP share similar 
acute clinical presentation, AIP tends to be more clinically severe than VP at least 
(17). Hypertension appears to be present in people presenting with AIP (27). 
Long-term complications of AHP 
Long-term complications of AHP include diseases such as chronic kidney disease 
(CKD), hypertension (15, 27, 28) and HCC (8, 29-37).  
CKD appears increased in over 50 per cent of individuals with symptomatic AIP and 
over 60 per cent of these individuals have hypertension (28). Symptomatic AIP 
appears to predict CKD independent of hypertension, even if the latter is a known 
risk factor of CKD (28). This is supported by the finding that ALA and PBG promote 
tubular and arteriolar injury of the kidney (28).   
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HCC risk appears to be dramatically increased in persons with AHP. However, the 
discrepancies between studies’ reported risk estimates of HCC in AHP is large (29, 
32-34, 37). The vast majority of detected cases have presented with HCC, although 
cases of cholangiocarcinoma (CC) have also been reported (34). Therefore, study I 
investigated the risk of primary liver cancer (PLC), rather than just HCC. 
Predominantly AIP has been linked to PLC, and the evidence for VP has been less. 
Two cases of HCC in HCP have been reported (34, 38). Typical PLC risk factors, 
such as alcohol abuse or chronic hepatitis, are not generally reported in persons with 
AHP and PLC, and only about 26 per cent have presented with liver cirrhosis (39), 
compared to 80 to 90 per cent of persons with HCC in the general population (40). 
Likewise, the majority of cases with AHP and PLC are women compared to two-
thirds of men in the general population. Further support for an association between 
AHP and PLC is the finding of an increased urinary ALA and PBG in persons with 
PLC compared to individuals with AHP and no PLC (39). Although the 
pathophysiology underlying the development of PLC in AHP is not well understood, 
a dominant theory proposes that ALA may be carcinogenic (41). Except for the rare 
case report, there is no evidence that people with an AHP diagnosis are at an 
increased risk of any other type of cancer (31, 42, 43), despite the accumulation of 
porphyrins and associated precursors in other areas of the body than the liver, such as 
the kidneys.    
It has been found that individuals with symptomatic AHP, and especially recurrent 
acute attacks patients, report low health-related quality of life (44-46), chronic 
symptoms, such as chronic pain and fatigue, between attacks (47-49), and have high 
rates of unemployment and access of long-term sick leave or the disability pension, 
especially in persons having recurrent attacks (15, 47, 50). However, it is difficult to 
determine from these studies if the risk for such life events was comparatively 
increased to the general population or confounded by age, sex or socio-economic 
factors. Symptoms outside of an acute attack, which patients ascribe to their AHP, 
tend to be diffuse, such as chronic pain and fatigue (49). However, these same factors 
affect about 30 per cent of the adult Norwegian population, especially women, and is 
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also the most common cause for disability benefit and long-term sick leave as well as 
years lived with disability (51).  
AHP has been associated with an increased risk of premature mortality. In a cohort 
study of individuals who had been hospitalized for their AIP in Sweden and 
Denmark, Linet reported a 1.9-fold increased risk of premature death (43). Specific 
medical diagnoses that contributed to premature death included cancer and ischemic 
heart disease (43). However, the findings were inconsistent between Sweden and 
Denmark, and selecting AIP cases based on hospital administration may have biased 
the findings, despite attempts by the investigators to minimise this. Other studies 
report despite a high prevalence of hypertension, no increased risk of mortality due to 
cardiovascular disease (27). However, a significant risk was observed for death due 
to renal impairment (27).    
1.1.2 Porphyria cutanea tarda (PCT) 
Pathogenesis, epidemiology and clinical presentation and management 
PCT is a non-acute cutaneous hepatic porphyria and the most common form of 
porphyria worldwide and across Europe (8, 52). The prevalence in Norway is 
estimated at 1 in 10,000 (10). PCT results from a defect in the fifth enzyme in the 
synthesis of haem, and specifically a defect of the hepatic enzyme uroporphyrinogen 
decarboxylase (UROD) (1). The impaired UROD activity causes accumulation of 
uroporphyrinogens and heptacarboxylated porphyrinogens in the liver, and the 
corresponding water-soluble porphyrins act as photosensitisers in the skin, giving 
symptoms in the form of bullae, fragile skin, hypertrichosis and hyperpigmentation, 
mostly in the sun-exposed areas of the hands and face (53). Symptom debut typically 
occurs in middle age and has an approximately equal sex ratio.  
PCT occurs both as an acquired (sporadic PCT) and an autosomal dominant 
hereditary form (familial PCT), in which mutations in the UROD gene can be 
identified (54). An acquired toxic type has also been reported, but will not be 
discussed further in the current thesis (55). Although UROD activity is reduced by up 
to 50% in familial PCT, exogenous factors are required for overt disease, and clinical 
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penetrance is low (56). The two types of PCT are clinically indistinguishable, 
although familial PCT tends to occur at an earlier age. Susceptibility factors for both 
include excess iron, HCV and hepatitis B virus (HBV), excessive alcohol intake, 
smoking, human immunodeficiency virus (HIV) and oestrogens (53, 54, 57-61). 
However, given the already reduced UROD activity, persons with familial PCT have 
a lower tolerance to exogenous factors and, therefore, such factors tend to be less 
strongly correlated with this form of PCT (54, 59, 62). In most populations, familial 
PCT occurs in 20 to 25 per cent of affected individuals (59, 63-65). However, in 
Norway, the proportion is much larger and estimated closer to 50% (54). This is 
partially explained by a founder mutation originating in the north-western part of 
Southern Norway (66). Another explanation may be that Norway has been a low 
endemic area of HCV infection, a major trigger of sporadic PCT (67), compared to 
other European countries (64). However, to our knowledge, reliable estimates of 
HCV infection across Norway are not currently available.   
PCT is strongly associated with mild to moderate chronic iron overload, especially in 
the liver (68). PCT is also associated with diabetes mellitus (69). Treatment includes 
the removal of precipitating factors, reduction of iron overload by repeated 
venesection or low dose chloroquine treatment to reduce excretion of uroporphyrins 
in the liver (70, 71). Such therapies result in prolonged remission in most patients, 
although relapses occur in some individuals (72, 73). 
Long-term complications 
PCT is associated with HCC (43, 74-76). HCV, HBV and excessive alcohol intake 
constitute the main risk factors for HCC in the general population (77, 78). 
Histopathological examinations of liver biopsy samples show liver abnormalities, 
including liver cirrhosis, in some patients with PCT. If such hepatic injury is caused 
by porphyrins or their associated precipitants, iron overload, hepatitis or hepatotoxins 
is unclear (79). It has been hypothesised that HCC risk is greater in PCT cirrhosis 
than other types of cirrhosis and that HCC risk may be greatest in persons with a long 
treatment delay (80). This has been partially supported by animal studies 
demonstrating the induction of liver tumours in mice with induced experimental PCT 
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(81); and a finding from a case-control study that patients with PCT had a 5-fold 
increased risk of HCC compared to matched control patients with chronic liver 
disease (76). However, the small and highly selective sample of this latter study 
makes drawing strong conclusions difficult. Others have suggested that with 
improvements in the diagnosis and consequently reduced treatment delays in persons 
with PCT, hepatic injury from PCT would be reduced, and excessive risk of HCC 
may no longer be apparent (82). Whether PCT increases the risk for HCC above the 
risk caused by common HCC risk factors and PCT susceptibility factors are still 
controversial. It also remains unclear if the risk for HCC warrants selective HCC 
surveillance, as recommended for individuals with AHP (83). Other than HCC, the 
risk for other malignancies is less clear. A single cohort study suggests that patients 
with PCT may have an increased risk of lung cancer and suggest that porphyrins may 
increase susceptibility to tobacco-related cancers (43). Case studies suggest that PCT 
may also be precipitated by leukaemia (84-86), and therefore, reverse causality is an 
important factor in the design of a study investigating PCT and cancer. Persons with 
PCT may also have an increased risk of premature death (43), although the finding is 







The overall aim of the current project was to investigate the long-term consequences 
of AHP and PCT. Specific research aims included: 
- to investigate the absolute risk of malignancies in persons with AHP and if 
this risk was increased compared to the general population, with a specific 
interest in PLC (study I) 
- to investigate the absolute risk of malignancies in persons with PCT and if this 
risk was increased compared to the general population, with a specific interest 
in the risk of PLC, as well the increased risk of premature death and to 
compare differences of these risks between persons with familial and sporadic 
PCT (study II) 
- to investigate if persons with AHP were at increased risk of long-term sick 
leave, disability pension and premature death compared to the general 
population and if there were any differences in risk between asymptomatic 
and symptomatic gene carriers (study III). 
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3. Methods 
Table 1. Overview of materials and methods  
Paper Study I-AHP and cancer Study II-PCT, cancer and 
mortality 
Study III-AHP, long-term sick 
leave, disability pension and 
mortality 
Main aim To examine the risk of 
malignancies in persons 
with AHP compared to 
the general population, 
with a specific interest in 
primary liver cancer 
(PLC) 
To examine the risk of 
malignancies and of 
premature death in persons 
with PCT compared to the 
general population, with a 
specific interest in 
hepatocellular carcinoma 
To examine if persons with AHP 
were at increased risk of long-term 
sick leave, disability pension and 
premature death compared to the 
general population 
Study design A population-based 
nationwide cohort study 
A population-based 
nationwide cohort study 




All Norwegian residents 
aged 18 years or older 
from 01-2000 to 12-2011 
All Norwegian residents 
aged 18 years or older from 
01-2000 to 12-2016 
All Norwegian residents aged 18 
years or older from 01-1992 to 12-
2017 (long-term sick leave), 01-
1992 to 12-2016 (disability leave) 




From the study start to the 
date of emigration, death 
of first primary cancer or 
study end, or whichever 
occurred first 
From the study start or the 
date of the respective 
person’s 18th birthday to the 
date of death, first primary 
cancer or study end, or 
whichever occurred first 
From the study start or the date of 
the respective person’s 18th 
birthday to the date of death event 
of interest or study end, or 
whichever occurred first 
Exposure AHP PCT AHP 
Reference/ 
unexposed 
General population General population; persons 
with a history of alcohol 
abuse/dependence 
General population; matched 
cohort (10 controls to each case) 
Main 
outcomes 
Primary liver cancer 
(PLC). ICD codes: C22 
(ICD-10) and 155 (ICD-
7) 
Hepatocellular carcinoma 
(HCC). 155.0 (ICD-10) and 
C22.0 (ICD-7), and  
premature death (all-cause 
and disease specific - 
mortality) 
Long-term sick leave, disability 
pension and premature death (all-




Survival analysis using 
Cox proportional hazards 
regression models (time 
scale=time on the study). 
Meta-analysis to explore 
sex differences in risk of 
PLC 
Survival analysis using Cox 
proportional regression 
models (time scale=age on 
the study). Competing risks 
regression to assess risk 
compared to persons with a 
history of chronic alcohol 
abuse/dependence 
Survival analysis using Cox 
proportional hazard regression 
models for the primary outcomes 
(time scale=age on the study).  
Differences in diagnostic reasons 
assessed by Poisson regression. 
Annual events for long-term sick 
leave episodes and total days, 
determined by zero-inflated 
negative binomial regression 
Adjustments Year of birth, sex, highest 
attained education 
Year of birth, sex, highest 
attained education 




Male and female; 
symptomatic and 
asymptomatic AHP 
Familial PCT, sporadic 
PCT, unclassified PCT 
Hospitalised, non- hospitalised, 
asymptomatic, unclassified AHP 
Sensitivity 
analyses 
Reduced cases with 
outcome and AHP by 1. 
Assessed effect of non-
consent 
E-value Assessed impact of non-consent 
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3.1 Data sources 
3.1.1 The National Registry 
The National Registry contains demographic information of all Norwegian residents 
since 1960 and is administered by the Norwegian Tax Administration (87). 
Specifically, the registry contains information regarding gender, date of birth, place 
of birth, date of emigration and date of death. 
3.1.2 The Norwegian Porphyria Centre  
The Norwegian Porphyria Centre (NAPOS) is located at Haukeland University 
Hospital, Bergen, Norway and was established in December 1999. All individuals 
with symptomatic disease and asymptomatic AHP and overt PCT are invited to 
participate in the national Norwegian Porphyria Registry. The registry was 
established in 2002 and obtained status as a national medical quality registry in 2012. 
Data collection is based on participant informed consent, and the data is derived from 
patient-reported questionnaires supplemented with biochemical and genetic 
laboratory results. The questionnaires are disease-specific (i.e., AIP questionnaire 
specifically for AIP patients, VP questionnaires specifically for VP patients, HCP 
questionnaire specifically for HCP patients, PCT questionnaires specifically for PCT 
patients) and include a rich array of data elements concerning diagnosis, provoking 
factors, symptoms, treatment, medication, lifestyle habits, daily life activities and 
comorbidities. Laboratory data of porphyrin and porphyrin precursor analyses are 
included when samples are sent for routine analysis as well as by biobanking. In 
2018 there was a 71 per cent response rate to the registry (PCT=71%, AIP=69%, 
VP=69%, HCP=71%), which means that 71 per cent of all known porphyria patients 
and porphyria gene mutation carriers in Norway participate by completing the 
questionnaire at the time of diagnosis and every second to fourth year thereafter (88). 
In addition to the registry, NAPOS maintains an administrative database of all known 
persons with a porphyria diagnosis, updated periodically with life status.     
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3.1.3 The Cancer Registry of Norway 
Since 1951 all physicians, hospitals and pathology libraries across Norway were 
instructed by law to notify all new neoplasms to the mandatory national Norwegian 
Cancer Registry (89). Cancer information comes from several independent sources, 
thus securing a high grade of accuracy and completeness (89). Up until 1992, 
diagnoses were based on a modified version of the 7th revision of the International 
Classification of Diseases (ICD-7). The International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3) was used since 1993 for coding the site 
(topography) and the histology (morphology) of neoplasms. Since 1986, non-solid 
tumours have been coded according to a separate coding system. All new primary 
cancer diagnoses for each individual are recorded, meaning one person can have up 
to several primary cancer diagnoses.  
3.1.4 Norwegian Cause of Death Registry 
The Norwegian Cause of Death Registry, maintained by the Norwegian Institute of 
Public Health since 2014, records all deaths that occur in Norway and deaths of 
citizens who die abroad. The digitalised registry maintains records since 1951. The 
registry has a coverage greater than 98% (90). Diagnostic codes are prepared in 
accordance to the ICD, with the 10th revision implemented in Norway in 1996 and 
includes both the underlying cause of death (i.e., the disease or injury which initiated 
the death) and contributing causes of death (i.e., other significant factors related to 
the cause of death but not related to the disease or condition causing it).  
3.1.5 Statistics Norway 
Statistics Norway (SSB) administers the National Education Database, which 
maintains individual-based education statistics for all residents of Norway from 
primary to tertiary level since 1970 (91). Information about students aboard was 
included in 1986 (91). This information is available for 90% of the population, with 
missing data mostly comprising of persons who immigrated to Norway. 
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3.1.6 Norwegian Labour and Welfare Administration 
The Norwegian Labour and Welfare Administration has maintained records 
regarding disbursements of different benefits, including long-term sick leave benefit, 
medical and occupational - rehabilitation and disability pension, since 1992 (92). The 
database includes data on the start and end date of each benefit for all Norwegian 
residents and, for long-term sick leave, the total number of days it was accessed. 
Diagnostic codes for physician-certified long-term sick leave episodes, medical 
rehabilitation and disability leave, included the second revision of the International 
Classification of Primary Care (ICPC-2), ICD-9 and 10. 
3.1.7 Record linkage 
Precise record linkage between the data sources was performed in 2012 and again in 
2018 by Statistics Norway (SSB). Study I was based on record linked data from 
2012, whereas study II and study III were based on data that was record linked in 
2018. All personal identification numbers were replaced by unique study numbers, 
producing a de-identified research database for further analyses.   
3.2 Study design and study population 
We conducted a population based, nationwide, cohort study using registry data. Data 
regarding the exposure (AHP/PCT diagnosis) were collected before the outcomes 
(e.g., cancer diagnosis/cause of death). The study sample comprised of all Norwegian 
adult residents alive during the study periods. The study period varied between the 
three studies and outcomes according to the availability of data.  
3.2.1 Study I (AHP and cancer) 
Study I included 251 adults with a confirmed AHP diagnosis (AIP, n=222; VP, n 
=21; and HCP, n=8) and 4,398,546 adults from the general population (reference 
population). The study period was from January 2000 to December 2011. The 
primary endpoint was a primary first cancer diagnosis and, therefore, people with a 
cancer diagnosis registered in the Cancer Registry of Norway (not including non-
melanoma skin cancers) prior to 2000 were excluded. 
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3.2.2 Study II (PCT, cancer and mortality) 
Study II included 612 adults with a confirmed overt PCT diagnosis from January 
2000 to December 2016. To avoid issues of reverse causality, 23 persons who had a 
cancer diagnosis proceeding PCT symptoms were excluded from analyses where 
cancer was the primary outcome. 
3.2.3 Study III (AHP, mobidity and mortality) 
Study III comprised of 319 persons with a confirmed diagnosis of AHP (AIP=281; 
VP=30; HCP=8). The study period was from January 1992 to December 2016 for 
investigating the risk of disability pension; January 1992 to December 2017 for 
investigating the risk of long-term sick leave and January 1996 to December 2017 for 
investigating the risk of premature death.  
3.3 Exposures, outcomes and confounders 
3.3.1 Exposures (AHP/PCT diagnosis) 
NAPOS is tasked with the responsibility of diagnosing the porphyrias across Norway 
and, therefore, has an overview of almost all Norwegian porphyria patients (10). 
When the centre was established in 1999, all laboratories diagnosing the porphyrias 
were contacted and requested to send information about all patients with a porphyria 
diagnosis (10). Porphyria diagnoses are established in accordance with diagnostic 
algorithms by Badminton et al  (93). Biochemical testing of porphyrins and their 
precursors was conducted by the Department of Medical Biochemistry and 
Pharmacology, Haukeland University Hospital and DNA sequencing of the UROD, 
porphobilinogen deaminase (PBGD), coproporphyinogen oxidase (CPOX) and 
protoporphyrinogen oxidase (PPOX) genes by the Centre for Medical Genetics and 
Molecular Medicine at the same hospital. NAPOS offers predictive testing to all 
AHP patients’ family members. However, predictive testing is voluntary and in 
addition, Norwegian law requires the patients themselves to inform their relatives. 
Thus, not all family members at risk undergo predictive genetic testing. Additional to 
the Norwegian Porphyria Registry, NAPOS maintains a record of all porphyria 
diagnoses. In 2017, a request of signed consent was mail posted to persons with a 
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confirmed porphyria diagnosis and not included in the registry to link their porphyria 
diagnosis and laboratory data to other national registries. Persons who were deceased 
with a confirmed porphyria diagnosis and not included in the registry were included 
in all studies, as permitted by the Regional Ethics Committee. In total, the 
participation rate of persons with a known AHP diagnosis, both symptomatic and 
asymptomatic, or PCT diagnosis was 73% for study I, 78% for study II and 77% for 
study III.  
It is common to classify persons with an AHP diagnosis either as having 
symptomatic disease (referred to as ‘manifest’ in study I) or being an asymptomatic 
predictively tested gene mutation carrier (referred to as ‘predisposed cases’ in study 
I). Broadly speaking, the former refers to persons who have had at least one acute 
attack throughout their life and/or skin symptoms in the case of VP/HCP, whereas 
the latter refers to people who have been found to be genetically predisposed to AHP 
porphyria but remain symptom-free. However, to date, there remains no consensus 
on the definition of an acute attack. For study I we classified persons as symptomatic 
if they had reported having had porphyria related symptoms, in the form of acute 
attacks, and/or skin lesions if VP or HCP in the Norwegian Porphyria Registry. 
Patients reporting acute attacks experienced abdominal pain as their main symptom 
(92%). Other frequently reported symptoms were nausea, obstipation, muscular pain, 
muscular weakness, palpitations, red-brown coloured urine, fatigue and psychiatric 
symptoms. For study III we further classified individuals with symptomatic AHP as 
either ‘hospitalised AHP’ if they reported having been hospitalised at least once due 
to an acute attack or non-hospitalised AHP’ if they reported having had symptoms of 
porphyria but never having been hospitalised specifically for acute attack. Eighty-one 
per cent of the persons with hospitalised AHP had a urinary PBG concentration four 
times greater than the upper reference limit (URL) recorded outside of an acute 
attack, compared to 66 per cent of persons with non-hospitalised AHP, and 26 per 
cent of asymptomatic AHP gene carriers. Of the individuals who had not responded 
to any questionnaires and, therefore, could not be classified as symptomatic or 
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asymptomatic, 37 per cent had a urinary PBG concentration four times greater than 
the URL.   
Persons with PCT were classified as having familial (inherited) or sporadic PCT 
based on sequencing of the UROD gene. Participants for which DNA sequencing had 
not been performed were registered as unclassified PCT. 
3.3.2 Outcomes 
Study I (AHP and cancer) 
The primary outcome of Study I was primary liver cancer (PLC) defined with the 
following ICD codes: C22 (ICD-10) and 155 (ICD-7). The most prevalent 
histological form of PLC (90% of cases) is HCC (ICD-10: C22.0; ICD-7: 155.0). 
Intrahepatic cholangiocellular carcinoma (CC) (ICD-10: C22.1; ICD-7: 155.1) is less 
common; however, cases of AHP and CC have been reported (34). Secondary 
outcomes included other cancer diagnoses in which 3 or more persons with an AHP 
diagnosis from our study sample were affected. Therefore, these diagnoses were 
exploratory, rather than determined a priori, and the findings from these secondary 
outcomes considered hypothesis-generating for future studies. The secondary 
outcomes for study I included: kidney cancer, including the renal pelvis=C64-65 
(ICD-10), 180 (ICD-7); endometrial cancer=C54 (ICD-10), 172 (ICD-7); breast 
cancer=C50 (ICD-10), 170 (ICD-7); and prostate cancer=C61 (ICD-10), 177 (ICD-
7). We classified all non-PLC malignancies using the ICD codes C00-96 (ICD-10), 
excluding PLC codes and non-melanoma skin cancer codes. 
Study II (PCT, cancer and mortality) 
The primary outcomes for study II (PCT, cancer and mortality) included HCC (ICD-
7: 155.0; ICD-10: C22.0), and overall risk of premature death. Secondary outcomes 
included the following cancer diagnoses of a priori interest: all sites (ICD-7: 140-
207; ICD-10: C00-96, D45-47), lung (ICD-7: 162; ICD-10: C33-34); and leukaemia 
(ICD-7: 207; ICD-10: C91-95, D45-47). We also investigated the following 
secondary outcomes related to a premature death and of a prior interest: malignant 
neoplasms (ICD-10: C00-96), diabetes mellitus (ICD-10: E10-14), cerebrovascular 
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diseases (ICD-10: I60-I69), chronic obstructive pulmonary disease (ICD-10: J43-44), 
and diseases of the liver (ICD-10: K70-77, B15-19, E83.1). Similar to study I, we 
explored cancer and mortality diagnoses in which three or more persons with AHP 
were affected. These diagnoses included: colon/rectum (ICD-7: 153-154; ICD-10: 
C18-C21), gallbladder and biliary tract (ICD-7: 156; ICD-10:C23-24), pancreas 
(ICD-7: 157; ICD-10; C25), lung (ICD-7: 162; ICD-10: C33-34); non-melanoma 
skin (ICD-7: 191; ICD-10: C44), breast (ICD-7: 170; ICD-10: C50), prostate (ICD-7: 
177; ICD-10: C61), and all-second primary cancers.  
Study III (AHP, mobidity and mortality) 
The primary outcomes for study III included long-term sick leave, disability pension 
and overall risk of premature death. The first 16 days of a sick-leave absence is 
compensated by the employer and paid for by the Labour and Welfare 
Administration (NAV). Therefore, long-term sick leave is defined in study III as any 
sick leave absence of 17 days or more as it is not possible to acquire data regarding 
sick leave episodes of a shorter duration. Sick leave can be granted for a maximum of 
one year. In Norway, to qualify for disability pension, a person has to be aged 18 
years or older and have a permanently reduced earning capacity by at least 50% due 
to illness or injury. Disability pension is seen as a last resort, and a person must first 
be on sick leave for one year before they qualify for work or medical rehabilitation, 
and if they still are unable to return to work, can be granted disability pension. 
Therefore, it is rare that an individual will return to full-time work following 
admission to disability pension.    
Specific diagnoses for long-term sick leave coded using the ICPC-2 included: 
general and unspecified (A01-A99), weakness/tiredness general (A04), abdominal 
pain (D01-D02, D06), high blood pressure/hypertensive disorder (K85, K86, K87), 
ischemic heart disease (K76), muscle/joint – pain/symptoms (L18, L19, L20), 
neurological (N01-N99), psychological (P01-P99), acute stress reaction (P02), 
feeling depressed (P02), depressive disorder (P03), endocrine/metabolism dis. other 
(T99) and urology (U01-U99). Diagnoses for disability pension were coded using the 
ICD-10, and included: neoplasms (C00-96, D45-47), disorders of porphyrin and 
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bilirubin metabolism (E80), mental and behavioural disorders (F00-F99), epilepsy 
(G40), diseases of the circulatory system (I00-I99), hypertension (I10-I15), ischemic 
heart disease (I20-I25), diseases of the musculoskeletal system and connective tissue 
(M00-M99) and renal failure (N17-N19). The following underlying causes of death 
were investigated using the ICD-10: malignant neoplasms (C00-96, D45-47), HCC 
(C22.0), renal carcinoma (C64), type I diabetes (E10), hypertension (I10-I11), 
ischemic heart disease (I20-I25), and renal failure (N17-N19). 
3.3.3 Potential confounders 
Sex and age 
Incidence and risk factors for many cancers are strongly influenced by sex and age. 
In the general population, HCC has a strong male predominance, with males 
estimated to have a four-fold increased risk of PLC (94). PLC risk also increases 
with advancing age (95). Although asymptomatic AHP gene carriers have an equal 
sex distribution, there is a female predominance among persons with symptomatic 
AHP. Despite there is roughly an equal sex distribution for persons with both familial 
and sporadic PCT in Norway (54), triggering factors do vary between the sexes. In 
relation to long-term sick leave and disability leave, female sex and older age status 
are strongly correlated factors (96). Therefore, given the association between age and 
sex with both the exposures AHP and PCT, as well as our outcomes, study results 
that fail to account for these factors are likely to be confounded and invalid. Previous 
studies investigating the association between PLC and AHP have found very 
different sex profiles compared to the general population, while the risk is also 
highest in old age. Therefore, sex and age are important covariates that need to be 







C  A  Y 
Figure 2. Controlling for measured covariates C (age, sex) reduces 
confounding of the relationship between the exposure A (e.g., AHP) and 
the outcome Y (e.g., PLC) (97).  
Socio-economic status (SES), liver diseases and chronic alcohol abuse 
Socioeconomic status (SES) refers to a person’s social standing. It has been found to 
negatively correlate with  cancer outcome (98), premature death (99), long-term sick 
leave and disability pension (96). These effects hold constant in Norway, despite a 
policy of universal access to health care for over 70 years (100). In relation to long-
term sick leave and disability pension, the strong correlation with lower socio-
economic status is mostly explained by health behaviours, such as diet, alcohol, 
smoking, exercise and differences in working conditions (96). In relation to 
premature death, studies in Norway have found that persons with tertiary education 
live five to six years longer and have better health than those with lower education 
(99). A recent study further found substantial and increasing disparities in life-
expectancy by household income in Norway (101). The relationship between SES 
and cancer incidence is more complicated. SES is positively correlated with the 
incidence of prostate and breast cancers (102, 103), and a negatively correlated with 
lung, colorectal and PLC (98, 104-106). Some studies have indicated that this 
negative association may reflect variances in exposures to lifestyles or carcinogens 
that determine cancer risk (103).  
While socioeconomic status is viewed as a multidimensional latent variable, 
encompassing education, income level and occupation, education may be the best 
measure for health related socioeconomic status of the three constructs. It is 
generally available for both sexes and excludes few members of the population. It 
encompasses much of the same information as occupation and household income but 
also reflects individual differences in terms of access to information. Including all 
three measures can cause multicollinearity problems (i.e., correlation coefficient of 
above 0.8 or 0.9) with regression models. Factor analytical techniques, which are 
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often considered for creating a single score from multiple variables, is not 
appropriate for formative models. Therefore, the highest educational level achieved 
was used alone as the best estimation of SES. 
While socioeconomic status may not directly affect PLC incidence, it acts as a proxy 
for major unmeasured risk factors, such as chronic alcohol intake and HCV and 
HBV, which are more prevalent in persons with greater SES deprivation (104). PLC 
and PCT, especially sporadic PCT, share some of the same risk factors, such as liver 
disease and chronic alcohol use. However, reliable statistics of these factors do not 
exist at the population level. Therefore, SES was included as a proxy for these factors 
for Study II (Figure 3). 
 
U  C  A  Y 
Figure 3. Controlling for measured covariate C (SES), even in the presence 
of unmeasured variables U (e.g., liver disease, health behaviour), 
eliminates, or more likely reduces, confounding of the relationship between 
exposure A (e.g., AHP) and the outcome Y (e.g., PLC, long-term sick 
leave), even though C itself is not a common cause of A and Y (97).  
 
Although symptomatic AHP may be triggered by alcohol and drugs like barbiturates, 
there is no indication that this patient group differ in relation to PLC risk factors 
compared to the general population. Furthermore, unlike persons with PCT, liver 
disease due to lifestyle factors is uncommon. Some cases of liver cirrhosis have been 
reported in persons with AHP and PLC (34). However, it is unclear if this association 
is due to porphyrins/precursors, old age or other factors (34). We included SES as a 
proxy of potential “backdoor” confounders in the analysis of study I, in accordance 
with the principals of confounder selection outlined by VanderWeele (97). However, 
we expected there to be a small overall effect for this adjustment. In regards to social 
benefits, sickness benefits and disability pension increase with decreasing SES (107) 
and, therefore, the inclusion of education was included as a potential confounder for 
study III, again in accordance to the principals of confounder selection outlined by 
VanderWeele (97) .    
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As stated above, a challenge of study II was to adjust for spurious effects of liver 
disease and chronic alcohol abuse in the causal pathway between persons with PCT 
and HCC, given this data was not available for the entire population. Therefore, as 
well as including SES as a proxy in adjusted regression analyses of the entire 
population, we conducted a sub-group analysis, investigating the risk of HCC in 
persons with PCT compared to a subset of persons with a diagnosis of chronic 
alcohol abuse/dependence. This control group was derived from medical registrations 
in the social benefits registries. Chronic alcohol abuse/dependence was defined by 
the following codes: ICPC-2: P15; ICD-9: 303, 305.0; ICD-10: F10 specifically, 
from long-term sick leave, medical and vocational rehabilitation and disability 
pension registries. The group is by no means a complete list of individuals with this 
diagnosis across Norway.  
3.4 Statistical methods 
3.4.1 Analyses of primary endpoints 
Stata/SE Version 14 and 15 for Windows was used for all statistical analyses 
(StataCorp Stata Statistical, Software, College Station, TX, USA).  
The incidence rate is a measure of the number of new occurrences of a disease over a 
given time period or age divided by the corresponding person-years at risk among 
members of the source population (108). Person-years at risk is the summation of all 
persons within a study by the potential time at risk of the outcome of interest of the 
study (109). Incidence rate was used across all studies to indicate absolute risk both 
in the exposed and the general population.  
In its simplest form, the risk ratio refers to the ratio of the incidence of an outcome in 
the exposed compared to the unexposed or reference population and provides the 
strength of association between the exposure/risk factor and the outcome. Although 
there are some important differences between them, there are a number of specific 
measures of risk estimates. In the current project, risk ratios were estimated by 
hazard ratios (HRs), subdistribution hazard ratios (SHRs) and incident rate ratios 
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(IRRs), dependent on the aim of the analysis and statistical procedure used. A risk 
ratio of one indicates that the exposure is not related to the outcome; a risk ratio 
greater than one indicates that an increase in exposure is associated with increased 
risk of the outcome, and a risk ratio less than one indicates the outcome is decreased 
by the exposure.   
To compare the time-to-event from exposure to the main outcomes between the 
exposed and general population, HRs with 95% confidence intervals (CIs) were 
estimated using Cox proportional hazards regression models (110). The porphyria 
diagnosis AHP/PCT (no/yes) or AHP/PCT subtype (e.g., symptomatic AHP) was the 
exposure and cancer, cause of death of interest, or social security benefit (no/yes) the 
outcome. Time on the study was used as the time scale for study I, whereas age on 
the study was used as the time scale for study II and study III. Entry time was from 
the time (study I) or age (study II, study III) of the start of the study. Additionally, for 
study II and study III, persons aged 18 years after the study start were included at the 
time of their 18th birthday (i.e., left truncated). The exit time was the time (study I) or 
age (study II, study III) of the event (e.g., cancer) or censoring (emigration (study I 
only), death due to other factors, or end of study follow-up, whichever occurred first. 
For study III, we additionally censored for the time a person entered disability 
pension when assessing long-term sick leave. Units of time were measured in years 
for study I and study II (due to the lack of availability of month of cancer diagnosis 
for privacy reasons) and months for study III.  
The Cox model was stratified by birth cohorts to adjust for cohort effects, roughly 
equating to the time of a generation of 20 years. The multivariate models adjusted for 
the covariates sex, age (as a continuous covariate in study I and as a continuous time-
scale in study II and study III), and educational attainment. The proportionality 
assumption of the Cox models was assessed by inspecting Kaplan-Meier curves and 
the log(-log(survival)) versus log(time) graphs for fixed covariates, including time-
dependent covariates in the model for all covariates, and tests of the non-zero slope. 
In the rare circumstance in which a covariate violated the assumption of 
proportionality of the hazards, the covariate was consequently entered as time-
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dependent in an extended model. Obtained level of education was categorized into: 
no schooling, compulsory education (year 1-10), upper secondary education (11-13, 
or 14 years if including post-secondary non-tertiary education), tertiary education 
(14+ years), and unspecified/missing.  
Given a combination of a rare exposure (i.e., AHP/PCT) and many outcomes of 
interest (e.g., PLC) of the current project, we were mostly underpowered to 
investigate interactions. Therefore, where interaction analysis was not possible, we 
stratified on subtypes in which we thought the hazard ratio might differ. Specifically, 
we conducted separate Cox regression models for sex and persons aged 50 years or 
older in study I. We also stratified by sex in a meta-analysis in study I (details 
below). Study III, in which outcomes such as long-term sick leave and disability 
pension were common, we investigated interactions between the exposure and 
educational attainment (tertiary or upper secondary vs less education) and sex, and 
none were found.  
3.4.2 Analyses of secondary endpoints 
In study II, we compared the risk of cancer and causes of death in persons with PCT 
to persons with a history of chronic alcohol abuse/dependence, who have a high 
mortality risk by a competing risks regression survival analysis. Death, due to other 
causes, was the competing risk in the analysis. Persons with both PCT and a history 
of chronic alcohol abuse/dependence (n=17) were excluded from this analysis. 
In study III, we conducted a Poisson regression to investigate differences in the 
diagnostic reasons for long-term sick leave and the disability pension between 
persons with AHP and the general population. All analyses were conducted using 
robust standard errors to estimate the IRRs and CIs, and were offset for months on 
the study (defined as month and year of exit minus month and year of entry).  
To assess total annual episodes and days of long-term sick leave in persons with 
AHP and sub-types, we estimated IRRs and CIs using a zero-inflated negative 
binomial regression (ZIBR) with robust standard errors. The total number of days or 
events was divided by each participant’s number of years on the study to obtain an 
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annual rate for each person. For computational efficiency in predicting the IRR and 
to adjust more precisely, we frequency-matched ten randomly selected controls to 
every AHP case, on sex, age at study start and educational attainment for this 
analysis. Frequency matching, especially with so many controls, will result in 
approximately the same results, but with some loss of power (111).  
3.4.3 Sensitivity analyses 
For study I in which both the exposure and the outcome were infrequent, we 
conducted a sensitivity analysis to investigate the effect on the HR by subtracting one 
case with AHP and the outcome of interest. So, for example, we subtracted the total 
number of cases with AHP and PLC by one and re-ran the analysis to investigate the 
overall effect. We also investigated the impact of including all known persons with 
AHP in the denominator while specifying no new cases of PLC and AHP, to 
investigate the maximum potential for selection bias by non-consenters in a crude 
analysis. Overall, these changes had a negligible effect on the estimates and 
interpretations of the study findings.  
For study II we calculated the evidence value (E-value) for each adjusted HR. The E-
value is the minimum size of a risk ratio of an unmeasured confounder that is 
required to explain away the association between the exposure and the outcome. The 
E-value formula is: hazard ratio (HR) + sqrt[HR x (HR-1)] (97).  
For study III, we investigated the impact of non-consent bias specifically for the 
outcome of premature death by including all known persons with an AHP diagnosis 
in the denominator in a crude analysis.   
3.4.4 Literature review and meta-analysis 
For study I, we conducted a random-effects meta-analysis of the PLC risk in men and 
women. In October 2016, a systematic literature search for relevant studies was 
performed using the PubMed database with the following search terms: “Porphyrias, 
Hepatic” [MeSH Major Topic]) AND "Liver Neoplasms"[MeSH Major Topic]. This 
resulted in 46 hits. Following quality assessment and rejection of case series and 
basic research studies, seven studies investigating specifically AHP were identified. 
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An additional four studies of interest were further identified by scanning the 
reference lists of these publications. Of the 11 published studies examining AHP and 
PLC, there were six studies which reported separate risk ratios for men and women 
(29-34). The meta-analysis included these estimates and ours. Risk ratios were 
stratified by sex and then weighted using the inverse-variance method to calculate 
separately pooled risk ratios for females and males.  
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3.5 Ethical considerations/ approval 
All data were de-identified of personal identification numbers before delivery to the 
investigators. The study protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected by approval by the Regional Committees for 
Medical and Health Research Ethics, Norway (reference number: 2012/753). 
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4. Summary of main results 
4.1 Acute hepatic porphyria and cancer risk (study I) 
From 2000 to 2012 and across 251 persons with AHP, we found 9 cases of PLC 
(AIP=8, VP=1), constituting a burden of 30% of all neoplasms reported for AHP 
participants. The annual incidence of PLC was 0.35% in all adults and 0.63% in 
persons aged 50 years or older, compared to 0.003% in the general population. In the 
adjusted analysis, this constituted a 108-fold increased risk of PLC compared to the 
general population (95% CI: 56, 207). In an exploratory analysis, we found a 7-fold 
(95% CI: 2.4, 23.1) and 6-fold (95% CI: 2.0, 19.3) increased risk of kidney and 
endometrial cancers, respectively. In total, we found no evidence of an increased risk 
of other malignancies or non-PLC malignancies in total compared to the general 
population.   
In a sensitivity analysis, we found that hypothetically decreasing the number of cases 
with AHP and PLC by one over the study period would reduce the hazard ratio to 96 
(95% CI: 56, 205). If we included all known persons with an AHP diagnosis who did 
not consent to the Norwegian Porphyria Registry, hypothetically specifying that no 
new cases of PLC were found, the annual incidence would decrease to 0.27% and 
hazard ratio to 86 (95% CI: 45-166).  
In our study, 67% of persons with PLC and AHP were female compared to 37% in 
the general population. When we stratified the Cox regression by sex, females had a 
168-fold increased risk (95% CI: 75-376) and males a 70-fold increased risk (95% 
CI: 22-217). In a meta-analysis of our and previous studies, the pooled risk ratio 
estimate was 131 for women (95% CI: 92-186) and 51 for men (95% CI: 37-71), 
suggesting that the relative risk of PLC in persons with AHP is different between the 
sexes (Figure 4). When comparing persons within the AHP cohort, we found that 
eight out of the nine cases with PLC had symptomatic AHP, compared to 59% of 
cases without PLC (p=0.09). The risk in persons with only symptomatic AHP was 
160 compared to the general population (95% CI: 80-321).  
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Figure 4. Forest plot showing an inverse-weighted random-effect meta-
analysis of the risk of primary liver cancer in persons with acute hepatic 
porphyria. Results are stratified by sex. The area of each square is 
proportional to the study’s weight in the meta-analysis and the diamonds 
represent the measure of the risk ratio estimate for each sex; 95% 
confidence intervals for these estimates are shown (horizontal lines). ES, 
effect size. The X-scale is logarithmic.  
4.2 Porphyria cutanea tarda and cancer/mortality risk 
(study II) 
We found 6 cases of HCC and 3 cases of gallbladder or biliary tract cancer in 589 
persons with PCT from 2000 to 2016. This constituted a 19.7-fold (95% CI: 8.8, 
44.0) increased risk of HCC and a 6.8-fold (95% CI: 2.2, 21.0) increased risk of 
gallbladder and biliary tract cancer (Figure 5). The excess risk was reduced when 
compared to persons with a history of chronic alcohol abuse/dependence (HCC, 
SHR=3.1, 95% CI: 1.2, 7.7; Gallbladder and biliary tract cancer, SHR=4.0, 95% CI: 
1.1, 14.4). We also observed a 1.6-fold increased risk for lung cancer compared to 
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the general population, although the lower bound confidence interval was slightly 
below one (Figure 5). There was no indication of an increased risk of other 
malignancies, or all malignancies, compared to the general population or persons 














































































Persons with sporadic PCT (aHR=1.4, 95% CI: 1.1, 1.8) and unclassified PCT 
(aHR=2.5, 95% CI: 1.9, 3.1) were at an increased risk of premature death compared 
to the general population. There was no increased risk observed for individuals with 
familial PCT (aHR=0.8, 95% CI: 0.1–1.1). Mean age at death was 71.8 years for 
persons with sporadic PCT (95% CI: 68.9–74.7), 72.1 years for persons with familial 
PCT (95% CI: 67.0–77.1) and 73.3 years (95% CI: 70.5–76.1) for persons with 
unclassified PCT, compared to 78.5 years (95% CI: 78.4–78.5) in the general 
population. Specifically, persons with PCT had a 1.4-fold (95% CI: 1.0, 1.9) 
increased risk of death by malignant neoplasms (all-sites), a 5.5-fold excess risk of 
death by liver diseases (95% CI: 2.5, 12.2), and a 9.9-fold excess risk of death by 
alcohol or drug overdose (95% CI: 4.7, 20.8). We found no evidence of an increased 
risk of premature death due to an underlying diagnosis of diabetes mellitus, ischemic 
heart disease, cerebrovascular diseases, chronic obstructive pulmonary disease or 
renal failure. 
4.3 Acute hepatic porphyria and long-term sick leave, 
disability leave and risk of premature death (study III) 
Persons with AHP were more likely to access long-term sick leave (aHR=1.5, 95% 
CI: 1.3, 1.7) at least once over their lifetime, and to access disability pension 
(aHR=1.9, 95% CI: 1.5, 2.4). They were, on average, 5 to 6 years younger at the time 
of first long-term sick leave episode and disability pension compared to the general 
population. A dose-response for both long-term sick leave and disability pension was 
suggested by the different AHP subtypes, with the highest risk detected in persons 
with hospitalised AHP, less so in persons with non-hospitalised AHP and 
unclassified AHP, while no excess risk was detected in asymptomatic AHP gene 
carriers (Figure 6). Compared to the general population, we observed no increased 
























































































































































































Compared to matched controls, persons with symptomatic AHP, hospitalised and 
non-hospitalised, had on average 1.6 (95% CI: 1.1, 2.2) and 1.4 (95% CI: 1.2, 1.6) 
times more total days of long-term sick leave per year, respectively. This equated to a 
difference of 4.5 (0.4, 8.6) and 3.0 (95% CI: 1.1, 4.8) additional days of annual long-
term sick leave, respectively. There was no difference found between matched 
controls and asymptomatic gene carriers or persons with unclassified AHP. 
Additionally, compared to matched controls, persons with non-hospitalised AHP 
were expected to have 1.3 (95% CI: 1.0, 1.7) times more episodes of long-term sick 
leave per year. No differences were detected, however, between matched controls 
and persons with hospitalised AHP (IRR=1.1, 95% CI: 0.8, 1.5), the unclassified 
group (IRR=0.9, 95% CI: 0.7, 1.1) or the asymptomatic group (IRR=0.9, 0.7, 1.2), in 
relation to annual episodes.     
The main diagnostic reason for long-term sick leave in patients with porphyria was 
‘endocrine/metabolism/nutritional disorder’ (n=52 patients), a category that AHP 
diagnoses fall under. Following this ‘psychological symptoms/disorders’ were 
common, both in AHP and the general population. However, compared to the general 
population, individuals with an AHP diagnosis had an increased risk of a long-term 
sick leave episode due to ischemic heart disease (aIRR=3.0, 95%CI: 1.4, 6.6), 
endocrine/metabolism/nutritional disorder (aIRR=46.2, 95% CI: 36.2, 59.0), 
urological symptom/disorder (aIRR=2.4, 95% CI: 1.4, 4.3) and high blood pressure 
(aIRR=2.1, 95% CI: 1.2, 3.7).  
The main diagnostic reason for accessing disability pension was a diagnosis of AHP 
(ICD-10: E80.2), n=16. Of these 16 cases, six were classified as hospitalised AHP, 
nine non-hospitalised AHP and one was unclassified. Other diagnostic reasons for 
accessing disability pension included mental and behavioural disorders, n=10; 
diseases of the circulatory system, n=10; and diseases of the musculoskeletal system 
and connective tissue, n=10. There was, however, no evidence that risk of disability 
due to these specific diagnostic groups was elevated among persons with AHP 
compared to the general population, except for diseases of the circulatory system 
(aIRR=3.8, 95% CI: 2.0, 7.1). 
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The most prominent cause of mortality was HCC (ICD-10: C22) (n=6, adjusted 
mortality rate ratio (aMRR)=84.4, 95% CI: 37.8, 188.2). Other causes of death of 
interest, but with a count less than four, included: renal carcinoma (C64): n=2; 
porphyria (E80.2), n=2; and renal failure (N17-19), n=2. There was one additional 
count of HCC, three counts of hypertensive disorder (I10, I11) and five other cases of 





5.1 Summary of main findings 
We found evidence of a substantial risk of PLC in persons with AHP and 
considerable risk of HCC in persons with PCT, compared to the general population. 
The finding is significant given the very poor prognosis of PLC (112). However, 
although the hazard ratios were large, the absolute risk estimates were small, 
especially for PCT. For example, the annual incidence of PLC in individuals with 
AHP was 0.35%, meaning that for every 285 persons with AHP screened annually, 
we would expect to find a single case of PLC. On the other hand, we would need to 
test annually over 1,429 persons with PCT to find an individual instance of HCC, 
even though in 2017, only 780 persons were registered with a PCT diagnosis in 
Norway.  
We also found evidence that persons with AHP had an increased risk of kidney and 
endometrial cancers and persons with PCT gallbladder and biliary cancer. However, 
given the findings were exploratory, novel and the total number of positive cases, 
small, the results are seen as hypothesis-generating rather than confirmatory, and 
further research is required. We found evidence of an increased risk of premature 
death in persons with sporadic PCT due to lifestyle diseases, such as liver diseases 
and alcohol or drug overdose. On the other hand, we found no evidence of an 
increased risk of early death in persons with AHP. Persons with symptomatic AHP 
were more likely to access long-term sick leave and disability pension than the 
general population due to their porphyria, and this appeared pronounced in persons 
with more severe disease. 
5.2 Methodological considerations 
5.2.1 Study design  
Double-blinded randomised control trials (RCTs) are seen as the gold standard in 
epidemiology (113), given that by randomly allocating participants to receive the 
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exposure or treatment, potential confounders are also randomly distributed between 
the experimental groups. If well designed with a sufficient sample size this results in 
two groups that differ based on only the allocated exposure, whereas potential 
confounders, including confounding factors not even considered by researchers, will 
be roughly equally distributed between the groups by chance (114). Therefore, 
researchers can be more confident that a strong association between the exposure and 
outcome is indicative of a causal relationship. RCTs do, however, suffer from some 
inherent critical limitations. For example, given the expense of RCTs, they are very 
rarely population-based and generally highly selective of study participants (113). 
Most importantly, randomly allocating persons to receive an exposure, such as 
porphyria, in epidemiological studies is usually not ethical or even possible. 
In observational research, participants are not randomly allocated to each group, but 
rather have the exposure of interest or do not. Therefore, observational research does 
not present the same ethical issues inherent to RCT design (115, 116). Observational 
studies, like the current project, can also be population-based and less selective than 
RCTs, meaning there is better generalisability of the results (115). Such studies are, 
however, prone to systematic differences between the groups, and such variations 
may be confounding factors. Researchers can control for potential measured 
confounders by several experimental or statistical methods, such as matching or 
regression. Residual confounding cannot, however, be ruled out in such studies. 
Therefore, traditionally, researchers have been cautious when drawing causative 
inferences from observational studies.  
There are three main types of observational studies, including cohort studies, case-
control studies and cross-sectional studies. Of the three, cohort studies are considered 
to provide the best evidence, yielding better validity than case-control studies, and 
given that the exposure is measured before the outcome of interest, generally 
eliminate issues of reverse causality, which is an inherent issue in cross-sectional 
studies (108, 117). The current project used a registry-based cohort design (118). 
Although the cohort is historical and the study aims developed following data 
collection, the exposure was measured before the outcome at the study start or 
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follow-up, and independent of the study aims. This type of cohort design is 
advantages because data collection is complete at the time of the studies conception 
and study findings are, therefore, expedited. A limitation of this design compared to 
cohort studies which collect data prospectively is that often information on potential 
confounding is not available, at the population level at least. Nordic countries have 
developed population-based registries, such as the Cancer Registry of Norway, over 
decades and enable linkage at the level of the individual by the unique personal 
identifier. The Norwegian personal identification number is an 11 digit personal Id 
used nationally and assigned to every Norwegian resident at the time of birth or 
immigration by the National Population Register (87). The Id is used ubiquitously in 
every facet of Norwegian society from health appointments and employment to the 
access of social benefits, and across all data sources used in the current project. In 
health and national registries, the number enables data linkage, dramatically reducing 
the risk of duplication, even in the case of twins.                 
5.2.2 Causal inferences 
Epidemiological studies are typically concerned by the causal relationship between 
an exposure and the outcome. However, spurious effects, or bias, from common 
causes are likely in observational studies. The definition of a confounder has been 
disputed in the causal inference literature (119). However, a useful description of the 
term confounder is a factor associated with the outcome conditional on the exposure 
and not causally related between the exposure and outcome pathway (120). 
According to this definition, a confounder is a factor that leads to an outcome, 
entirely or in part, and this effect is mistakenly attributing to the exposure. 
Conditioning on a confounder, either by restriction, stratification or statistical 
adjustment, is considered to remove the bias by comparing groups within strata of 
covariates (114). 
A standard method to explore graphically and theoretically, the presence of common 
causes and, therefore, potential confounders, is to draw a directed acyclical diagram 
(DAG) (121-123). DAGs are directed, in that the relationship between two variables 
is depicted by arrows, representing causal relationships, and the relationship between 
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two variables cannot be unidirectional (i.e., they cannot cause each other). DAGs are 
acyclical, which means that there is no feedback loop where a variable causes itself. 
DAGs can have either directed/open paths, in which all arrows point in the same 
direction, reflecting a causal relationship; backdoor paths, in which two variables 
share the same cause, reflecting confounding (Figure 9), or closed pathways, in 
which two variables have the same effect, also known as collider bias (Figure 10) 
(120). According to VanderWeele, in situations where complete knowledge of a 
causal diagram is lacking, researchers should control for each covariate that is a 
cause of the exposure, outcome, or both; excluding any variables known to be an 
instrumental variable; and include as a covariate, any proxy for unmeasured variables 
known to be a cause of both the exposure and the outcome (97). 
 
 
C  A  Y 
Figure 9. DAG illustrating confounding (C) from the exposure (A) to outcome (Y) 
 
 
A  Y  S 
Figure 10. DAG illustrating collider bias (S), in which A (exposure) and Y (outcome) 
have a common effect     
5.2.3 Choice of statistical methods  
Cox proportional hazards regression 
Cox proportional hazards regression models are used extensively throughout all 
studies presented in the current thesis. The hazard ratio, produced by the Cox model, 
evaluates the ratio of the hazard rate between the exposed and unexposed at each unit 
of time, rather than the ratio of the cumulative incidence. In this way, the hazard of 
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the outcome can vary over time between groups and can be interpreted as the 
instantaneous risk of developing the event at that time, assuming that a person 
remains at risk of the outcome at that time (109). Cox regression assesses time-to-
event while accounting for person-time, potential confounders as covariates and 
censoring and, therefore, is typically the preferred method for assessing cohort 
studies. Relative risk ratios or odds ratios, on the other hand, produced by Poisson or 
logistic – regression, respectively, evaluates the cumulative risk or odds of an event 
and cannot account for censoring. The traditional Cox model assumes, however, that 
the HR between the exposed and unexposed remains constant over time (i.e., 
proportional hazard assumption). However, time-varying covariates can be included 
in a so-called extended Cox model by including an interaction term of the covariate 
by time.   
Competing risks regression 
In study II, we compared the risk of cancer and causes of death in persons with PCT 
to persons with a history of chronic alcohol abuse/dependence. Given the latter group 
are more likely to die young before they are at risk of cancer, we conducted a 
competing risks regression survival analysis calculating the adjusted subdistribution 
hazard ratio (aSHR). A competing risk is considered an event that hinders the 
observation of the outcome of interest or modifies the chance that this outcome will 
occur (26). This was the case for persons with a history of alcohol abuse/dependence, 
who were at a higher risk of early death due to their condition before they could 
develop cancer or die from other causes. When calculating the SHR, those having a 
competing event are maintained in the risk set and only censored when the event of 
interest occurs. Consequently, over time, a higher proportion of the risk set becomes 
full of individuals who have had a competing event before that time. Therefore, 
whereas the hazard function (Cox proportional regression), is the incidence of a 
particular outcome of interest in individuals who are currently event free, the 
subdistribution hazard function (competing risks regression) is the incidence of a 
specific outcome of interest in individuals who have not yet experienced an outcome 
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of that type (124). It is noteworthy, however, that we found very similar outcomes 
when conducting a Cox proportional regression analysis.  
Zero-inflated negative binomial regression 
To assess annual events for total long-term sick leave episodes and total days in 
persons with AHP and subtypes (Study III), we estimated incident rate ratios (IRRs) 
and CIs using zero-inflated negative binomial regression (ZIBR) with robust standard 
errors. A binomial model was chosen because the outcomes of interest were count 
variables and, therefore, it is expected the response will follow a Poisson or binomial 
distribution, rather than a normal distribution. A binomial model was chosen over a 
Poisson model, because of overdispersion of our data. Negative binomial regression 
accounts for overdispersion of the mean by estimating a dispersion parameter, 
whereas Poisson regression holds constant the dispersion parameter equal to the 
mean, which may bias the standard errors (125). The model was zero-inflated given 
that most individuals never experience long-term sick leave and, therefore, there was 
an excess number of zero events. To account for differences in follow-up time, we 
offset the analysis by time-on-study. We also averaged the total number of sick days 
by years on study to estimate the annual rate. Lastly, we used frequency-matched 
controls, rather than the whole population, given persons of a similar age had a 
similar time of exposure.  
5.2.4 Precision 
Precision refers to how close estimates from different samples, or sampling 
distribution, drawn from the same population are to each other (126). It is dependent 
of the natural variation from the population they were drawn, sample size, the 
magnitude of the effect of the outcome under investigation and the level of random 
error an investigator is willing to accept in the final estimate. The latter is nearly 
always, and arbitrarily, set to five per cent, meaning that we reject the null hypothesis 
five per cent of the time when, in fact correct. In statistics, this relates to the Type I 
error rate and null hypothesis significance testing (NHST). However, NHST has 
several limitations (127), and we rarely depended on such methods in assessing the 
importance or weaknesses of our research findings. As the sample size of a 
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population increases in a study, the higher chance the sample will accurately 
represent the population under investigation. Consequently, as sample size increases, 
variation, usually measured by the standard error, will decrease as random error 
decreases. The standard error refers to the dispersion of the sample estimate around 
the population estimate. From the standard error, we can calculate the 95% CI, which 
can be interpreted as the probability, or our confidence, that our estimate will fall 
between the upper and lower bound probability distribution 95 per cent of the time 
(128).  
Investigating diseases with low prevalence, such as the porphyrias, is plagued by 
small sample sizes. Small sample sizes lead to more substantial standard errors and 
wide CIs, which in turn decreases statistical power. Statistical power relates to the 
probability of rejecting the null hypothesis when the null hypothesis is false and is 
the inverse of Type II error (129). However, we were able to mostly overcome this 
issue when investigating our primary outcomes at least, by conducting a population 
based cohort study. We included most persons with a known AHP/PCT diagnosis 
across Norway in the exposed groups and the entire population as our reference 
group, meaning that the sampling distribution and population distribution were 
virtually identical. Therefore, the confidence interval of the incidence of the 
reference population is minimal, indicating high precision of this estimate within this 
group. Importantly, this enables us to investigate not only the associations between 
AHP/PCT and shared outcomes, such as all-cause mortality or long-term sick leave, 
but also rare outcomes, such as PLC.  
Although we were sufficiently powered to investigate our primary outcomes, we 
lacked sufficient sample sizes to investigate some interactions of interest (see sub-
section ‘Interactions’ below for further detail). Additionally, some of our research 
findings may have been due to small sample bias and chance alone. For example in 
study I and study II we found an association between AHP/PCT and kidney cancer, 
endometrial cancer and bile duct and biliary tract cancer, respectively, even though 
only three cases of each cancer were detected during the study periods. We approach 
these research findings with caution, given several other factors other than just the 
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small number of cases. This included the exploratory nature of investigating such 
results (e.g., we were not interested in investigating endometrial cancer a priori when 
specifying our research aims) and the novelty of such findings (i.e., not reported in 
previous studies).  
It is important to note also the difference between risk ratios and absolute risk. Three 
cases among the exposed over a long study period among 251 or 589 do not indicate 
a high absolute risk, even if the proportion was more substantial than that observed in 
the reference population. Small number bias could also be used to criticise our 
findings of an increased risk of PLC in persons with AHP (n=9 of 256) and PCT 
(n=6 of 589). In study I we conducted a sensitivity analysis and decreased cases with 
the outcome of interest by one, hence from 9 to 8, and re-ran the analysis to observe 
the effect on the risk ratios. This decreased our aHR from 108 to 96 (95% CI: 48, 
192). Therefore, given the large effect size (i.e., aHR=108), the a priori nature of our 
investigation and support from previous findings, we do not believe that small 
sample biases our result regarding the association between AHP and PLC. If we were 
to apply the same scenario to study II, the aHR would decrease from 19.6 to 16.5 
(95% CI: 6.8, 39.7), and again, we can draw a similar conclusion. In study III we 
were mostly interested in prevalent outcomes, and therefore, small sample bias 
mainly was not an issue. We conducted, however, a sensitivity analysis to investigate 
the effect of non-consent bias for mortality using a crude analysis in study III (see 
sub-section ‘Selection bias’ below for further detail).    
Another benefit of using a cohort design for the current project was the very long 
study period over many years/decades, ranging from 12 years (study I) to 24 years 
(study III). Therefore, we were able to observe a higher number of incident cases of 
rare outcomes, improving each studies’ precision. 
5.2.5 Selection bias 
Selection bias occurs when the individuals included in the study are not 
representative of the target population (108). In DAG terminology, selection bias is 
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considered to cause collider bias, given that the probability of being selected is 
affected by the exposure and outcome (130).   
For the current project, the entire target population served as the reference group, 
ensuring the generalisability of the research findings. However, not all known 
persons with a confirmed diagnosis of AHP or PCT were included in the project. All 
participants of the Norwegian Porphyria Registry were included, as well as persons 
who were deceased by the study end. For studies II and III, we additionally sent out 
letters to all non-consenters of the Norwegian Porphyria Registry requesting their 
participation. The consent rate in study I was 73 per cent, and increased to 78 per 
cent for study II and 77 per cent for study III.  
Persons who did not participate may differ to those who did concerning the severity 
of their AHP/PCT or the outcome of interest. Individuals with symptomatic AHP 
may, for example, be more motivated to participate than an asymptomatic AHP gene 
carrier who have never had clinical symptoms. Evidence of this was semi-supported 
by the finding in Study I that a higher proportion of females (77%) than males (62%) 
participated, and as discussed previously, generally, more females present with 
symptomatic AHP than males. This could consequently bias the assessment of an 
association between AHP and the outcome of interest (131). It is difficult to predict if 
such a bias would lead to an under or over-estimation of the risk ratios. One could 
speculate that in the case of AHP, if the association between AHP and PLC was due 
to AHP per se, then including more persons with severe AHP would result in an 
overestimation. Additionally, all persons who were deceased by the end of the study 
were included in the analysis. Given the poor prognosis of PLC, it was less likely, 
although not impossible, that we, therefore, missed incident cases of PLC in non-
consenters. Due to this concern, we conducted a sensitivity analysis in study I, in 
which we reduced the hazard ratio of the main finding by the calculated per cent 
difference between the relative risk of the original study’s findings and, 
hypothetically, including all non-participants in the study and specifying no new 
cases of PLC. The two relative risk estimates were calculated in a simple two-by-two 
table, and do not adjust for covariates or account for time effects, such as person-
 57 
years or censoring, so is quite crude. The total impact of such covariates in study I 
was, however, minimal, as persons with AHP generally did not differ by such factors 
relative to the general population. Based on this estimate, we would observe an 18% 
reduction in the hazard ratio (sensitivity analysis, HR=86) from the original analysis.  
If we were to apply the same sensitivity analysis to our estimated aHR of PCT and 
HCC in study II, we would again expect an 18% reduction in the estimated HR, from 
19.7 to 16.2. In study III, again applying the above crude calculation would result in 
a 19% and 18% reduction of the aHR for long-term sick leave and disability pension, 
respectively. This would hypothetically reduce the HR from 1.5 to 1.2 for long-term 
sick leave and 1.9 to 1.5 for disability pension. This sensitivity analysis is 
hypothetical, and we do not know if any of the non-participants developed PLC in 
study I or study II. HCC, the most common type of PLC, has a poor three-year 
survival rate of between 10 to 50 per cent in non-operable HCC (132). Therefore, it 
may be argued that given the poor prognosis of non-operable HCC it is more likely 
than not that such individuals would be captured in our study within a small number 
of years as our sample did include all persons with AHP/PCT who were deceased by 
the study end. However, five-year survival may be greater than 70 per cent in 
selectively screened surgical HCC patients (133). Therefore, it is not certain all 
individuals with both PLC and HCC were captured. Regarding study III, given the 
frequent occurrence of the two outcomes, this scenario of no new cases among non-
participants is improbable. However, the sensitivity analysis demonstrates that even 
if no new cases were observed, the potential selection bias caused by non-
participation would have little effect on the interpretation of the risk ratios.  
Given the non-interventional nature of the study and that only pre-existing data 
would be investigated, we were granted permission by the Regional Ethical 
Committee to include all persons who were deceased by the end of the study period, 
irrespective of whether or not they had consented to participate in the Norwegian 
Porphyria Registry. Although this increased our sample and the study power, this 
was a particular source for selection bias when investigating mortality as an outcome 
in study II and study III. 
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In study III, we conducted a sensitivity analysis to reassess our risk ratio estimates of 
premature death and HCC, using the same method used above. The finding decreased 
the MRR from 1.3 to 0.7 for early death, suggesting that selection bias accounted for 
the observed increased risk in the initial analysis. This was further supported by the 
sub-group analysis, in which no evidence of an increased risk was observed in the 
three subtypes based on responses from the Norwegian Porphyria Registry (i.e., 
hospitalised AHP, non-hospitalised AHP and asymptomatic AHP gene carriers). 
Whereas, an increased risk was observed for the subtype formed of persons who 
were not participants of the Norwegian Porphyria Registry (i.e., unclassified). This is 
because this group comprised of a disproportionate number of deceased persons, 
whereas, the proportions of deceased persons in the other groups was not affected by 
this selection bias.        
NAPOS offers predictive testing to all AHP patients’ family members. However, 
predictive testing is voluntary, and Norwegian law requires the patients themselves to 
inform their relatives, which reduces the total number of genetically predisposed 
cases diagnosed and included in our project. Forty per cent and 39 per cent of 
individuals classified in study I and study III, respectively, were classified as 
asymptomatic. However, as discussed previously, a recent genetic study on AIP 
estimated clinical penetrance to be as low as one per cent (7). Therefore, the number 
of persons with asymptomatic AHP is underrepresented in study I and study III. It is 
difficult to say how this affects estimates for asymptomatic AHP gene carriers and 
how, if at all, persons unknown to NAPOS differ from those who were genetically 
tested. However, we have no reason to believe it is an important systematic bias. 
5.2.6 Information bias 
Information bias, also sometimes referred to as misclassification, occurs when there 
is a measurement error of the exposure, outcome or covariates and is a threat to the 
validity of research findings (126). Information bias can either be non-differential or 
differential. Non-differential bias arises when the measurement error in the exposure 
is unrelated to measurement error in the outcome (126), and generally, but not 
always, the bias affects estimates of risk ratios (e.g., HR) towards the null hypothesis 
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(134). Differential bias, on the other hand, refers to a measurement error which 
impacts groups disproportionately and can result in an under or overestimation of the 
risk ratios in either direction (135). 
Misclassification of the exposure 
All persons included in our project were diagnosed with either an AHP or PCT 
diagnosis by biochemical testing and/or DNA analysis, depending on the clinical 
presentation. Diagnostic tests were carried out by NAPOS, a European specialist 
centre, in collaboration with the Section of Porphyrin Analysis at the Department of 
Medical Biochemistry and Pharmacology, and the Centre for Medical Genetics and 
Molecular Medicine, Haukeland University Hospital. The procedure has been 
summarised elsewhere (136). However, the diagnostic procedure demonstrates good 
sensitivity and specificity, and definitive diagnosis in the case of DNA analysis for 
healthy at risk relatives. DNA analysis is further applied to differentiate sporadic and 
familial PCT (54). However, there is a small subset of cases where no mutation is 
found but where a genetic factor is still suspected, commonly referred to as type III 
PCT, which allows the possibility of some miss-classification.       
Individuals with AHP are classified as ‘symptomatic’ (referred to as ‘manifest’ in 
study I) or ‘asymptomatic’ (referred to as ‘predisposed cases’ in study I). Although 
different criteria may be applied, generally it is agreed that symptomatic AHP status 
is given to AHP gene mutation carriers who have had at least one hospitalised acute 
attack, characterised by severe abdominal pain in the absence of significant 
abdominal tenderness and the absence of any other cause for the symptoms (17), 
accompanied by an increased concentration of PBG and ALA in urine or blood (15, 
137). An acute attack usually persists for days to weeks (1). However, the clinical 
presentation of AHP may be non-specific, and symptoms could also reflect other 
illnesses (138). In remission from an acute attack, persons with AIP may still have 
increased ALA and PBG concentrations (15), whereas in persons with VP and HCP, 
concentrations usually normalise (1). In AIP the likelihood of having an acute attack 
is correlated with increasing levels of urinary PBG (137). However, asymptomatic 
AIP gene carriers may also excrete PBG concentrations greater than the URL (137). 
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Therefore, the values themselves have low levels of sensitivity and specificity when 
used to classify a person with AIP as symptomatic and asymptomatic, although this 
can be improved with multiple samplings.  
In study I, participants of the Norwegian Porphyria Registry self-reported by 
questionnaire if they had porphyria-related symptoms, in the form of acute attacks 
and/or skin lesions. Given the unspecific presentation of an acute attack, it is likely 
there is some miss-classification in study I of symptomatic patients. It is unlikely a 
patient would say they have never had an acute attack when they have, given the 
severity of an attack. It is, however, conceivable some patients ascribe various non-
AHP related symptoms to their predisposition for AHP, resulting in misclassification 
into the wrong subgroup (139, 140). We have also not used the demonstration of 
increased urinary ALA and PBG concentration as a requirement for the definition of 
a symptomatic person.            
In study III we classified persons with AHP into 4 subtypes: 1) ‘Hospitalised AHP’ - 
persons who reported having been hospitalised at least once due to an acute attack ’; 
2) ‘Non-hospitalised AHP’ - persons who reported having had symptoms of 
porphyria but never having been hospitalised specifically for an acute attack; 3) 
‘Asymptomatic AHP gene carriers’ - persons who reported never having had 
symptoms of porphyria over the study period; and 4) ‘Unclassified’ - persons with a 
confirmed AHP diagnosis but who had not participated in the Norwegian Porphyria 
Registry and, therefore, had not answered clinically relevant questions. Again, we 
were dependent on self-reported clinical data to define these subtypes, which may 
have resulted in some level of miss-classification. However, biochemical data was 
available for all persons. Eighty-one per cent of the persons reporting having been 
hospitalised for an acute attack had at one point in time a urinary PBG value four 
times the laboratory URL, compared to 65 per cent of persons not hospitalised, 25 
per cent of asymptomatic AHP gene carriers and 37 per cent unclassified.    
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Misclassification of the outcome 
Cancer diagnoses in study I and study II were derived from the Cancer Registry of 
Norway. The registry is a compulsory national registry with high levels of validity 
and completeness (89). Cancer information comes from several independent sources, 
thus securing a high grade of accuracy and completeness. Clinical notifications, 
pathological notifications and death certificates are the most used sources of 
reporting. In a validation study looking at registry data from 2001 to 2005, 
completeness was found to be very high at 99 per cent for overall cancer sites, and 
PLC and 94 per cent of cancer cases were morphologically verified, although with 
some variations according to cancer site (PLC=85%) (89). 
Cause of death was derived from the Norwegian Cause of Death Registry, which has 
high levels of completeness (90). We explicitly used the underlying cause of death 
when investigating the primary outcomes. One identified problem in the Cause of the 
Death Registry of Norway is the use of unspecific and non-meaningful ‘garbage 
codes’ in place of the underlying cause of death in some instances (10-20% of 
registrations in 2005) (141). However, in a more recent quality assessment of the 
Norwegian Cause of Death Registry, the registry was ranked in the highest group 
compared to other countries (142). Where diagnosis-specific causes of death, rather 
than all-cause mortality, was investigated, this may result in fewer identified incident 
cases. We, however, have no reason to believe any misclassification would be 
dependent on porphyria status. Thus, any such bias would likely be non-differential.      
Long-term sick leave and disability pension were derived from the Norwegian 
Labour and Welfare Administration. The data are primarily used for administrative 
purposes and, therefore, have not been validated. However, the information is 
ubiquitous, available for the entire population and include both persons consulted as 
inpatients and outpatients. Furthermore, benefits/payouts are based on the database. 
Any misclassification for accessing long-term sick leave or disability pension due to 
incorrect registration would be non-differential in study III. However, it is possible 
physicians may be more likely to code an AHP diagnosis as the reason for a visit or 
disability pension rather than using a more general code, such as ‘chronic fatigue’ or 
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‘chronic pain’. Therefore, although we found no evidence that individuals with AHP 
had a higher incidence of such health complaints, this may be inaccurate. 
5.2.7 Confounding 
Confounding in AHP 
Symptomatic AHP is extremely rare before puberty and more prevalent in females 
(21, 23). Therefore, age and sex were adjusted for by regression. Additionally, we 
adjusted for education as a proxy for lifestyle factors, such as heavy alcohol 
consumption, given the strong relationship to cancer in general, PLC specifically and 
early death. However, persons with AHP are counselled by NAPOS regarding 
lifestyle factors, such as alcohol avoidance, to reduce the risk of an acute attack 
(140). Further, as discussed previously, alcohol abuse and hepatitis are generally not 
observed in persons with AHP and PLC, and only a small proportion present with 
liver cirrhosis (39, 82). Overall, we found little evidence of confounding due to these 
three covariates. For example, in study I we found only a two per cent difference in 
hazard ratios from the crude to the adjusted - analysis when investigating the risk of 
PLC. In study III, additional to an adjusted analysis, we frequency-matched each case 
across the studies outcomes to 10 randomly selected controls from the entire 
population based on age in years at the study start, sex and educational attainment. 
The results from the matched analysis were essentially identical when compared to 
using covariate adjustment by regression. The largest difference was for the 
unclassified group, which may reflect that the group comprised of a more substantial 
proportion of the deceased, who were older at the start of the study, on average, than 
the other AHP subtypes and had lower educational attainment. The matched analysis, 
in this instance, may have more precisely adjusted for residual confounding than 
regression (143), possibly due to the small sample size in our exposure group. 
However, this difference did not affect the interpretation of the study results and 
generally supported the findings from the adjusted Cox regression analysis.       
Confounding in PCT 
Unlike AHP, triggering factors in both familial and, to a more considerable degree, 
sporadic PCT are known risk factors of cancer, HCC and premature death. It is 
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important to note, however, that not all individuals with sporadic PCT have liver 
disease or consume alcohol excessively, and susceptibility factors include, for 
example, exposure to oestrogens in women (59, 144). PCT typically develops later in 
life, and individuals with sporadic PCT in our study population had a mean age of 53 
years and familial PCT 48 years compared to 39 years of the adult reference 
population at the study start. Age is most likely one of the most critical risk factors 
for cancer and, obviously, an early death. In study II age was adjusted by the time-
scale in the Cox regression, rather than time on study, meaning incidence cases in 
persons with PCT and the reference population was compared at each year of age 
both in the crude and adjusted analyses. We additionally adjusted for calendar time in 
these models. Overall, there was a minimal change from 19.9 to 19.7 in the crude to 
adjusted analysis for HCC. This suggests that sex and educational attainment had 
little impact on the estimated HR. If we were simply to divide the annual incidence 
rate of HCC in persons with PCT (0.07%) by the annual incidence rate in persons 
with HCC from the reference population (0.002%) we would have a crude risk ratio 
of 35, suggesting that holding the effect of age constant in the model was important 
to not overestimate the impact of PCT on HCC.              
Ideally, we would have liked to have data regarding the diagnosis of liver diseases, 
such as HBV and HCV, and liver scarring, such as fibrosis and cirrhosis, across 
Norway, to adjust for these factors in our models. This would, therefore, enable us to 
more confidently state if high rates of HCC in persons with PCT was related to PCT 
per se or other co-dependent factors. However, to our knowledge, this data is not 
available. We included educational attainment. However, this was likely an imperfect 
proxy for the true confounder, as not all persons with a lower obtained education will 
develop liver disease and vice versa. Therefore, residual confounding by lifestyle 
factors is likely in study II.  
Residual confounding was modelled by calculating the evidence value (E-value) for 
each HR. This is defined as the minimum risk ratio an unmeasured confounder 
requires to explain away the outcome (97). The sensitivity analysis suggested that an 
unmeasured confounder would need to have a substantial hazard ratio of at 39, at a 
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minimum, to remove the effect of an increased HCC risk. Given that alcohol 
abuse/dependence and HBV are substantial risk factors for both PCT and HCC, it is 
possible that unmeasured confounding may explain away any direct relationship 
between PCT and HCC.      
We further compared the risk of HCC and other factors of interest to persons with a 
history of chronic alcohol abuse/dependence. This control group consisted of 30,468 
persons with a diagnosis of chronic alcohol abuse/dependence, identified through the 
Norwegian Labour and Welfare Administration registrations of social security 
benefits using ICPC-2, ICD-9 and ICD-10 codes. In this analysis, we found a 3-fold 
increased risk of HCC in persons with PCT, when compared to persons with a 
history of chronic alcohol abuse/dependence. We also found that although HCC risk 
was higher, persons with PCT had an 80% reduced risk of dying from non-malignant 
liver diseases than this reference population. This is interesting as alcohol 
abuse/dependence, and liver disease typically leads to cirrhosis and eventual HCC. 
The remaining high risk, although lower when compared to the reference population, 
suggests that alcohol was an essential confounder in the analysis, but may not 
thoroughly explain the association between PCT and HCC.  
5.2.8 Interactions  
Interaction occurs when the relationship between the exposure and outcome depends 
on a third interacting factor. Interactions can be tested by including a product term in 
a regression model. However, this procedure requires substantial statistical power 
and large sample sizes across categories. Given the small sample of the exposed and 
some outcomes, such as PLC, we were generally underpowered to investigate all 
interactions of interest. Another approach is to stratify/separate the regression 
analysis of the exposure and outcome by the third factor, with non-overlapping CIs 
of the risk estimates indicating interaction.   
In study I, consistent with previous studies, we found that although the risk of PLC in 
the general population was higher in men than women (37%), most cases with AHP 
and PLC were female (67%). This finding is generally supported by previous studies 
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(29, 31, 34, 35, 32, 33, 34, 35, 36). However, although the risk difference between 
men and women was substantial in study I, our study, as well as previous studies, 
was underpowered to conduct an interaction analysis. Therefore, we conducted a 
random-effects meta-analysis of the risk of PLC in men and women from six studies 
reporting separate risk ratios for men and women were identified, as well as our own 
(study I). Overall, we found that there was no overlap between the relative risk 
estimates between the studies, suggesting the relative risk of AHP and PLC was 
dependent on sex, with the risk being higher in women than men.  
In study II no interactions of PCT by educational attainment (tertiary or upper 
secondary vs less education) and by sex were found, although again there was limited 
power for interaction analyses. In study III, tests of interactions between AHP and 
sex were also investigated, although there was no evidence that the risk of accessing 
disability pension in AHP was dependent on sex (p-value for interaction=.919). 
5.2.9 External validity 
As discussed previously (see ‘study design’ section), observational population-based 
studies have excellent external validity compared to other methods, such as RCTs or 
case-control studies. In our project, the study population was essentially the same as 
the target population (i.e., Norwegian population), and, therefore, the findings are 
valid to this population. However, caution is required when comparing our results to 
other populations, due to some critical differences concerning the outcomes of 
interest.  
In relation to PLC, Norway has one of the lowest incidences of PLC across Europe. 
The age-adjusted rate per 100,000 was 3.0 in men and 1.4 in women in 2011, 
compared to 12.5 in men and 2.9 in women in France for the same year (112). The 
differences are quite stark compared to Spain, France and Italy, especially in men, 
where incidence is high (112). The differences are less compared to the Netherlands, 
Sweden, Denmark, Finland and Germany (112). Outside of Europe, the incidence of 
PLC is also very heterogeneous because of the variable prevalence of risk factors, 
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and are highest in Eastern and South-Eastern Asia and lowest in South-Central Asia 
and Western Asia (Figure 7) (145).   
 
Figure 6. Estimated age-standardised rates of incident cases of primary 
liver cancer for both sexes, worldwide in 2018. Reprinted from “Update in 
global trends and aetiology of hepatocellular carcinoma,” by Prashanth, R, 
et al. 2018, Contemporary oncology (Poznan, Poland), Vol. 22 (3), 141-
150. 
The prevalence of more common risk factors for PLC varies greatly between 
countries, which explains such national differences. Overall, such baseline 
differences in rates of PLC will affect risk ratio estimates, and we should be cautious 
when comparing such relative statistics between countries. Instead, we should 
compare absolute rates, such as annual incidence rates, although, again, caution is 
required given such values typically have not adjusted for potential confounders. One 
potential solution may be to calculate the population attributable fraction (PAF) for 
AHP and to compare this between countries. The PAF combines the prevalence of a 
risk factor in a particular population with the adjusted risk ratio and indicates the 
proportion of incident cases in a population attributable to a specific risk factor like 
AHP.   
Concerning long-term sick leave and disability pension (study III), given 
administrative, political and cultural differences between countries, direct 
comparisons are difficult. Even between Norway, Sweden, Denmark and Finland, 
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although patterns of access between demographic groups are similar (highest among 
women and older employees), rates of uptake are different (96). Generally speaking, 
Norway has a generous welfare system in which an employee’s job security is legally 
protected, and illness or disability does not constitute grounds for dismissal (43). An 
individual who is unable to work due to illness following one year of sick leave and 
vocational rehabilitation can be entitled to disability pension. Therefore, it follows 
that acute illness and chronic disability due to AHP and its late effects will manifest 
in access to long-term sick leave and disability pension in Norway. Where these 
protections do not exist, illness and disability due to AHP may result in 
unemployment, as reported elsewhere (50). However, although it may be difficult to 
generalise our findings from study III to populations outside of Norway specific to 
uptake of long-term sick leave and disability pension, the results are universally 
relevant. The effect of which is a loss of income and working years lost, and reflect 
an association between symptomatic AHP and chronic morbidity, regardless of how 
that manifests. 
5.3 Interpretation and contribution of the findings 
5.3.1 Porphyrins, porphyria and cancer 
In 1993 Batlle argued that accumulation of porphyrins, which occurs across disorders 
of porphyria, initiates carcinogenesis, and that cells with abnormal haem metabolism 
will increase cancer risk (146). Therefore, her model predicts that people with 
porphyria should be at an increased risk of cancer. Given that in the hepatic 
porphyrias, such as AHP and PCT, porphyrins and their associated precursors 
accumulate mostly in the liver, a higher incidence of liver cancer in these disorders 
follows. However, given these porphyrins and their precursors circulate and 
accumulate in other areas of the body, such as the spleen and kidneys (147, 148), it 
does not exclude observations of increased risk in other cancers as well.  
The aetiology of PLC cancer in AHP 
The exact underlying mechanisms that lead to tumour growth in the liver of persons 
with AHP is currently unknown, and several theories have been proposed (149-151). 
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One dominant hypothesis suggests that the accumulation of ALA may act via a pro-
oxidant and genotoxic effect (149). In Vitro, ALA has been found to damage plasmid 
and isolated DNA by reactive oxygen species (149). ALA has also been found to 
promote in isolated DNA the formation of radical-induced base degradation products 
(149). If this was true, then given that acute attacks are likely due to elevated levels 
of ALA (1, 152), then we may predict more persons with symptomatic AHP than 
asymptomatic gene carriers with normal concentrations of ALA and PBG to develop 
PLC. We found only one person with asymptomatic AHP and PLC of nine in total 
(study I), and this trend is a general finding across other studies (39). We also were 
able to demonstrate in a meta-analysis that females with AHP were more likely to 
develop PLC than males. Females are six times more likely than men to develop 
symptomatic AHP and, therefore, sex my act as a proxy in this instance for 
symptomatic disease. We would further predict that PLC is more likely in AIP than 
VP or HCP, given the chronic elevation of ALA is observed in some patients during 
remission in the former but not the two latter diseases. This is, however, difficult to 
investigate as VP and especially HCP are so rare in most countries, excluding South 
Africa. We found one case of VP with PLC out of 22 persons with VP. Therefore, if 
a small incidence of PLC in VP and HCP is due to differences in exposure to ALA or 
low incidence of VP and HCP, or a combination, is currently difficult to determine. 
Furthermore, PBG, uroporphyrin III, coproporphyrinogen III and 
protoporphyrinogen IX, which accumulate in the liver depending on type of AHP, 
may independently contribute to the tumour development (151).  
The aetiology of kidney cancer in AHP 
After the liver and bone marrow, the kidneys are third regarding the accumulation of 
ALA and amounts of haem synthesised (147). It is, therefore, possible that the same 
underlying mechanism was responsible for the observation of increased risks of PLC 
and kidney cancer in our study (study I). However, another possible explanation may 
be due to renal impairment. Kidney cancer is more common in patients with kidney 
failure, a known AIP comorbidity (28). However, the cause of this association 
between renal impairment and kidney cancer is not well understood (153). 
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The aetiology of HCC in PCT 
Unlike AHP, there is no accumulation of ALA and associated neurotoxicity in PCT. 
It has been suggested that under chronic conditions of exposure, such as when there 
is a long diagnostic delay, the accumulation of uroporphyrins in individuals with 
PCT may result in liver injury and the development of a liver tumour (74, 151). 
Rodent models further suggest the potential synergistic role of iron overload and 
genetic predispositions in this process (151). However, the confounding role of 
hepatotoxic factors, such as alcohol, which are implicated in the pathogenesis of PCT 
and HCC, makes it difficult to determine if PCT independently gives rise to HCC. 
Our findings provide some support for the hypothesis that PCT may by parallel, or 
interaction with, hepatotoxic factors, contribute to the formation of a liver tumour. In 
study II, we observed an increase in the risk after adjusting for educational attainment 
and comparing persons with PCT to persons with a history of chronic alcohol 
abuse/dependence. Of the six persons in our cohort with PCT and HCC, two had 
familial PCT, which is less associated with other types of liver disease or excessive 
alcohol intake than sporadic PCT (54). We also found a trend towards higher 
concentrations of total porphyrins and uroporphyrins in PCT patients with HCC 
compared to those without. However, the evidence is not clear, and the small number 
of persons with PCT and HCC, as well as the variability in the findings, limit our 
ability to draw any firm conclusions. It has been further suggested that with 
improved recognition and treatment of PCT, there will be a decrease in the incidence 
of HCC (82). We also found an increased risk of gallbladder and biliary tract cancer 
in persons with PCT. The finding is interesting, given that it is located beneath the 
liver and connected by the common hepatic duct. Although small numbers of 
observed cases tested over multiple cancers mean this could reflect a chance finding, 
the finding has been recently replicated in a Danish cohort (154).  
5.3.2 Long-term sick leave and disability pension in AHP 
In study III, we found a very high proportion of persons with hospitalised and non-
hospitalised symptomatic AHP accessed long-term sick leave at least once (82%) and 
disability pension (36%). The HRs were 1.5 and 1.9, respectively. However, given 
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that long-term sick leave and disability pension are common in the general 
population, it is not possible to observe a much higher risk ratio (i.e., ceiling effect). 
The median age when accessing disability pension was 46 years in persons with 
hospitalised AHP, which was substantially younger than the general population (21 
years) and other AHP subtypes. In a population-based study in Northern Sweden, a 
mean age of 45 years was reported in symptomatic patients accessing long-term sick 
leave or disability leave (15). We also found that persons who had been hospitalised 
at least once for an acute attack had 60 per cent more long-term sick leave days per 
year than the reference population. These findings suggest that severity in AHP may 
dramatically increase the number of working years lost due to disability.    
The most common symptoms associated with accessing long-term sick leave in study 
III included weakness/tiredness (6%), abdominal pain (2%), muscle/joint pain (3%), 
acute stress reaction (8%) and feeling depressed/depressive disorder (14%). 
However, such complaints were also common in the reference population, and we 
found no evidence that persons with AHP had increased risk of long-term sick leave 
due to these reasons. However, such medical complaints may have been coded with a 
porphyria diagnostic code instead, which was the most prevalent cause of long-term 
sick leave or for accessing disability pension. 
5.3.3 Causes of death in AHP 
We found an 84-fold excess risk of mortality due to HCC in persons with AHP 
compared to the general population. No other types of PLC were reported in the 
Cause of Death Registry. Although HCC has a very poor prognosis and low survival 
times, not all persons with AHP and HCC reported in study I were deceased in study 
III, suggesting the tumour was detected early and curatively treated in two persons.  
Another general finding regarding mortality and AHP is an excess risk of death due 
to renal impairment. Andersson and Lithner found that renal impairment was the 
cause in 9% of AIP deaths between 1978 and 1990 in Northern Sweden (27). In our 
study, renal failure was cited as the underlying cause in 4%, and as a contributing 
cause in 9% of deaths in individuals with AHP. Therefore, our results support 
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previous findings and suggest that renal disease remains a common cause of death in 
persons with AHP. 
Initially, in study III, we found a 30 per cent increased risk of premature death. 
However, the finding was isolated to the AHP unclassified subtype, who were 
overrepresented by persons included in our study due to their deceased status and, 
therefore, had not completed clinical questionnaires. As discussed previously, we 
conducted a sensitivity analysis which contradicted our initial finding. This stands in 
contrast to a study by Linet and colleagues (21), who reported a 90 per cent increased 
risk of premature death in AIP patients relative to respective Swedish and Danish 
populations, and specifically due to cancer and ischemic heart disease (excluding 
AIP as a cause of death) (43). Despite an increased risk of death due to HCC in 
persons with AHP in study III, the risk was not substantial enough to suggest persons 
with AHP were at an overall increased risk of early death.  
5.3.4 Causes of death in PCT 
In study II, we found that persons with PCT were at a seven-fold increased risk of 
dying from liver diseases compared to the general population. The specific diagnoses 
were alcoholic cirrhosis of the liver, hepatic alcohol failure, primary biliary cirrhosis, 
hepatic failure, and two cases of chronic HCV. Liver disease is associated with 
UROD inhibition and a known trigger of PCT (58, 62, 155, 156). It is, therefore, 
unsurprising to find an increased risk of mortality due to liver diseases in our PCT 
cohort. It is interesting though that of the six persons with PCT and HCC, none had 
liver disease listed as the underlying or contributing cause of their death. Although, 
one of the three persons with cancer of the gallbladder and biliary tract had cirrhosis 
of the liver listed as a contributing cause of their death. In addition, seven persons 
had died from alcohol poisoning or substance overdose, which constituted an 11-fold 
increased risk compared to the general population. Given the association between 
drug and alcohol abuse and liver disease, such as chronic HCV, and between liver 
disease and PCT, again, this finding is not surprising. Two of the six persons with 
liver disease and one of the seven who died due to alcohol poisoning or overdose due 
to substance abuse were female. This reflects a general finding that a larger 
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proportion of males than females with PCT have liver disease related to poor 
lifestyle, whereas many females develop PCT due to contraceptive use and not 
necessarily due to lifestyle factors (59). The median age of the persons who died due 
to alcohol poisoning or substance overdose was 53 years, compared to 63 years in 
persons who died from liver diseases and 73 years in persons with PCT, but who died 
due to other causes. Therefore, alcohol poisoning and substance overdose were the 
most significant causes of years of life lost.  
In a study published after the publication of study II, Danish researchers reported a 
20 per cent increased risk of premature death in all individuals registered with a PCT 
diagnosis from 1989 to 2012 compared to age and gender-matched controls (154). 
The researchers controlled for alcohol-related diseases, hepatitis, hemochromatosis, 
HIV, diabetes, acute mesenteric ischemia acute myocardial infarction, stroke, cancer, 
chronic obstructive pulmonary disease, and cirrhosis. Cause-specific diagnoses 
included non-malignant gastrointestinal diseases (HR=5.3), cancers of the gut 
(HR=2.1), liver/gallbladder (HR=11.24), and lungs (HR=2.17). Overall, the study 
supports our finding of an increased risk of premature death and due to the specific 
causes of cancers of the lung, liver and gallbladder. The differences in the magnitude 
of the HRs and cause-specific mortality may be explained by either national 
differences in baseline risk, these investigators including additional constraints for 
potential confounding, and/or these investigators not accounting for differences in 
all-cause mortality between individuals with familial and sporadic PCT.  
Lung cancer is associated with a poor prognosis (157). We found a 1.6 increased risk 
of lung cancer in PCT patients compared to the general population, although the 
finding was non-significant. Smoking was also the second most prevalent cancer, 
accounting for 16 per cent of all cancers. Christiansen et al reported a 2.2 increased 
risk of mortality in PCT patients compared to matched controls (154). Similarly, 
Linet et al reported a 2.9-fold increased risk of lung cancer compared to the general 
population in Swedish and Danish cohorts (43). Linet et al speculated that smoking 
alone could not explain the increased risk of lung cancer and that PCT may enhance 
susceptibility to cancer of the lung given evidence that smoking can lead to earlier 
 73 
onset of cutaneous symptoms in patients with sporadic disease (53). In our study, of 
the 6 persons who completed questionnaires, all were smokers, and given the strong 
association between lifestyle factors and PCT and the small size of the relative risk, it 
is difficult to rule out that this confounded the results. We also found no evidence of 
a difference in the diagnostic delay of PCT patients with a diagnosis of lung cancer 
to those without. Still the similar finding between the three studies supports the idea 
that cancer of the lung is prevalent among persons with PCT and an important 
contributing factor to premature mortality.  
5.4 HCC surveillance in persons with AHP and PCT 
When clinical symptoms of HCC present, typically the tumour is far advanced, and 
there are few therapeutic options. The European Association for the Study of the 
Liver (EASL) and European Organization for Research and Treatment of Cancer 
(EORTC) clinical practice guidelines for the management of HCC recommend 
biannual hepatic ultrasound screening by experienced personnel for individuals at 
high risk of HCC (127). This includes persons aged 50 years or older (127, 158).  
Additionally, according to expert opinion, an annual incidence cut-off of 1.5% would 
justify HCC surveillance in chronic hepatitis patients with cirrhosis, and 0.2% would 
justify surveillance in non-cirrhotic patients (159, 160). This is because the detection 
of HCC by ultrasound in the cirrhotic liver is more complicated and decreases the 
sensitivity and specificity of the diagnostic method (127). Although the porphyrias 
has not been considered in the above recommendations, two Swedish studies 
investigating surveillance in adults over the age of 50 years with AHP suggest that 
screening may lead to earlier tumour detection and reduced mortality rates in both 
individuals with and without symptomatic disease (33, 34). There is no such 
evidence, however, for persons with PCT. In study I we found an annual incidence of 
0.6 per cent in persons with AHP aged 50 years or older. Therefore, if we were to 
apply the cut-off for non-cirrhotic HBV patients, those with AHP, and particularly 
with symptomatic AHP, and 50 years or older should be targeted for screening as a 
high-risk group. In regards to PCT, we observed an annual incidence of HCC of 0.07 
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per cent, with an upper bound 95 per cent CI of 0.17 per cent. Additionally, unlike in 
AHP, confounding by concurrent cirrhosis cannot be ruled out in patients with PCT. 
Therefore, although surveillance is recommended for persons with AHP aged 50 
years or older, and especially with symptomatic disease, it cannot be currently 
recommended based on a PCT diagnosis alone. However it has been suggested that 
individuals with PCT should likely be tested for HCV/HBV infection and have a 
liver biopsy - with those with concurrent disease or cirrhosis included in a standard 
surveillance programme (75). Another recent recommendation is that individuals 
with AHP should additionally be vaccinated against viral HCV/HBV (161).  
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6. Conclusions  
The current thesis contributes with valuable knowledge to the long-term 
consequences of AHP and PCT. Specifically, we found that compared to the general 
population, persons with AHP, and especially symptomatic AHP, had an extremely 
high risk of PLC. We also showed in a meta-analysis that the risk was higher in 
women than in men. Our findings of moderately increased risks of endometrial and 
kidney cancers, however, need to be validated in future studies and may reflect 
chance findings. We also showed that compared to the general population, persons 
with PCT had a high risk of HCC and premature death due to lifestyle factors, such 
as alcohol abuse. We found moderate excess risks of gallbladder and biliary tract 
cancers, which again may be chance findings, and of premature death in persons with 
sporadic PCT. Given the risk of HCC was increased even when compared to persons 
with a history of alcohol abuse/dependence, PCT per se may contribute in part, or by 
interaction with lifestyle factors, to the development of HCC. Lastly, we found that 
individuals with symptomatic AHP were at increased risk of accessing long-term 
sick leave and disability pension due to their porphyria. We found no evidence of 
overall increased risk of premature death in persons with symptomatic or 
asymptomatic AHP, despite an increased risk of dying from HCC. 
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7. Future perspectives 
The very high risk of PLC in AHP has been confirmed, and although the underlying 
mechanisms are not entirely understood, there is good epidemiological evidence that 
the cause is due to something inherent to AHP, such as the accumulation of ALA in 
the liver. However, it remains unclear if risk of PLC is increased in asymptomatic 
AHP gene carriers and in VP and HCP. The costs and benefits of PLC surveillance 
programs for persons aged 50 years or older and with symptomatic AHP vs 
asymptomatic AHP gene carriers should be further explored. It would also be 
interesting to investigate if we can better identify high risk subtypes, such as 
asymptomatic high excretors of ALA and PBG, or recurrent attack patients. It is also 
of important scientific inquiry to investigate if prophylactic treatments to lower ALA 
and PBG concentrations and frequency of recurrent attacks reduce risk of PLC in 
these patients (1, 162, 163).    
The reason for the association between PCT and PLC is more complicated and 
remains controversial than the association between AHP and PLC. However, it is 
possible that with improvements to PCT diagnosis in the previous decade that 
observations of PLC may decrease over time due to reductions in diagnostic delay. 
Theoretically, these questions could be better investigated in a future study, by 
conducting a prospectively designed cohort study in which PLC risk factors, such as 
alcohol use, and HCV/HBV – status are recorded and adjusted for across groups. 
Ideally, this would be conducted across countries to improve the generalisability of 
research findings and increase the number of exposed cases with the outcome of 
interest. However, such studies are expensive, take years and require international 
collaboration.  
One example of an international collaborative effort investigating such questions is 
the European Porphyria Registry (164), which was established in 2012. However, the 
registry is not epidemiological, and although high-quality data regarding acute 
attacks, comorbidities and specifically PLC are collected, patients are included based 
on convenience. Another possible solution would be to combine Nordic registries, 
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especially between Norway, Finland and Sweden who all have excellent lists of 
persons with a porphyria diagnosis - and cancer population-based registries. This 
would improve small sample bias, although data regarding risk factors would still be 
incomplete.    
We found an increased risk of long-term sick leave and disability pension in persons 
mainly due to an AHP diagnosis. However, as previously discussed, there is 
presently no diagnostic test that may determine which symptoms may be caused by 
AHP, and it is uncertain under what conditions physicians use the code. For example, 
does the doctor use the code if a patient complains of chronic pain outside of an acute 
attack? Therefore, another interesting line of investigation for future studies could be 
detailed clinical reasons in persons with AHP who access long-term sick leave and 
disability pension. Ideally, the data would be collected via questionnaires to patients 
and physicians as well as subtracted from medical notes. Given we found some 
indication of a dose-effect in our analyses, it would be vital to collect physician-
reported data regarding if the patients have previously had a confirmed acute attack, 
and if the patient was treated for recurrent acute attacks of four or more attacks 
within a year. The Norwegian Porphyria Registry has in recent years started to 
collect this type of data from general practitioners.  
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